




(86) **Date de dépôt PCT/PCT Filing Date:** 2003/07/25
(87) **Date publication PCT/PCT Publication Date:** 2004/02/05
(45) **Date de délivrance/Issue Date:** 2015/06/02
(85) **Entrée phase nationale/National Entry:** 2005/01/25
(86) **N° demande PCT/PCT Application No.:** US 2003/023104
(87) **N° publication PCT/PCT Publication No.:** 2004/011647
(30) **Priorités/Priorities:** 2002/07/26 (US60/398,605);
2003/04/11 (US60/461,838); 2003/05/14 (US60/470,230)

(51) **Cl.Int./Int.Cl.** **C12N 15/113** (2010.01),
A61K 31/713 (2006.01), **A61P 31/14** (2006.01),
C12N 15/85 (2006.01), **C07H 21/02** (2006.01)
(72) **Inventeurs/Inventors:**
HAN, JANG, US;
SEO, MI YOUNG, US;
HOUGHTON, MICHAEL, US
(73) **Propriétaire/Owner:**
NOVARTIS VACCINES AND DIAGNOSTICS, INC., US
(74) **Agent:** BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) **Titre : PETITES MOLECULES MODIFIEES D'ARN D'INTERFERENCE ET LEURS PROCEDES D'UTILISATION**
(54) **Title: MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE**

**The Effect of siRNA_s on HCV Replication
In Huh 5-2 Cells**



(57) **Abrégé/Abstract:**

The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and method of making modified small interfering RNAs (siRNAs) using human Dicer.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/011647 A1

(51) International Patent Classification⁷: **C12N 15/11,**
A61K 31/711

(21) International Application Number:
PCT/US2003/023104

(22) International Filing Date: 25 July 2003 (25.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/398,605 26 July 2002 (26.07.2002) US
60/461,838 11 April 2003 (11.04.2003) US
60/470,230 14 May 2003 (14.05.2003) US

(71) Applicant (for all designated States except US): **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAN, Jang** [US/US]; c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608 (US). **SEO, Mi Young** [US/US]; c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608 (US). **HOUGHTON, Michael** [US/US]; c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608 (US).


(74) Agents: **PEET, Richard, C.** et al.; Foley & Lardner, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, D.C. 20007-5143 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

[Continued on next page]

(54) Title: MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE

The Effect of siRNA₅ on HCV Replication In Huh 5-2 Cells



(57) Abstract: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and method of making modified small interfering RNAs (siRNAs) using human Dicer.

WO 2004/011647 A1

WO 2004/011647 A1

MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

Published:

— *with international search report*

(48) Date of publication of this corrected version:

10 June 2004

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(15) Information about Correction:

see PCT Gazette No. 24/2004 of 10 June 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Modified Small Interfering RNA Molecules and Methods of Use

BACKGROUND OF THE INVENTION

The present invention relates to the field of nucleic acid detection and to the phenomenon of RNA silencing, or RNA interference (RNAi). RNA silencing constitutes a phenomenon wherein non-coding RNA molecules mediate specific gene suppression in an organism. In nature, the phenomenon protects an organism's genome from foreign, invading nucleic acids such as transposons, transgenes and viral genes.

The introduction of double-stranded RNA (dsRNA) into a cell triggers RNA silencing, which then degrades endogenous mRNA corresponding to the dsRNA. RNA silencing pathways involve a conversion of dsRNA into short interfering RNAs (siRNAs) that direct ribonucleases to homologous mRNA targets (Baulcombe *et al.*, 2001). An enzyme called Dicer processes the dsRNA into siRNAs, which are 20-25 nucleotides long. The siRNAs then assemble into endoribonuclease-containing complexes known as RNA-induced silencing complexes (RISCs). Subsequently, the siRNAs guide the RISCs to complementary RNA molecules, where the RISCs cleave and destroy the target mRNA. Small amounts of dsRNA can silence a large amount of target mRNA due to an amplification component of RNA silencing (Fire *et al.*, *Nature*, 391:806-811 (1998)).

The first evidence that dsRNA produces efficient gene silencing through RNAi came from studies on the nematode *Caenorhabditis elegans* (Fire *et al.*, *Nature*, 391:806-811 (1998) and U.S. Patent No. 6,506,559). Later studies in the fruit fly *Drosophila melanogaster* demonstrated that RNAi is a multi-step mechanism (Elbashir *et al.*, *Genes Dev.*, 15(2): 188-200 (2001)).

Although dsRNA can mediate gene-specific interference in mammalian cells (Wianny, F. and Zernicka-Goetz, M., *Nature Cell Biol.* 2:70-75 (2000) Svoboda, P. *et al.*, *Development* 17:4147-4156 (2000)), the use of RNAi in mammalian somatic cells is often limited by a triggering of dsRNA-dependent protein kinase (PKR), which inactivates the translation factor eIF2a, causes a generalized suppression of protein synthesis and often times causes apoptosis (Gil, J. and Esteban, M., *Apoptosis* 5:107-114(2000)).

Recently, siRNA of approximately 21 or 22 base pairs in length, corresponding to targeted RNA or DNA sequences, were shown to disrupt the expression of the targeted sequences in mammalian cells (Elbashir, S.M., *et al.*, *Nature* 411: 494-498 (2001)). However, it is not clear that all RNA or DNA sequences of a mammalian cell's genome are susceptible to siRNA. It is also uncertain that every mammalian cell type possesses the necessary machinery for effectuating gene-specific suppression using siRNA. Further, siRNA is of limited use for at least two reasons: (a) the transient nature of the suppression effect seen in cells where the siRNA has been administered, and (b) the necessity for chemical synthesis of siRNAs before their use (Tuschl, T., *Nature Biotech.*, 20: 446-448 (2002)). Also, since siRNAs are unstable *in vivo*, their long-term effectiveness is limited.

An invention that addresses these challenges will improve the utility of RNAi for treating human disease at the level of nucleic acid activity. In particular, such an invention will make RNAi a more practical therapy for viral infections, such as infections with HCV. Current therapies for such viral infections are very limited, and tend to have poor response rates.

SUMMARY OF THE INVENTION

The present invention provides double-stranded RNA (dsRNA) molecules that mediate RNA interference in target cells. In particular, it provides small interfering RNAs (siRNAs) that inhibit viral replication in infected cells. Preferred dsRNA molecules of the invention correspond to hepatitis C virus (HCV) nucleic acids, and inhibit replication of HCV in hepatic cells.

In another aspect, the invention provides modified dsRNA, including siRNA, molecules that are protected against nuclease degradation, but are able to inhibit viral replication in mammalian cells.

The invention also provides methods of inhibiting viral replication in infected cells by administering dsRNA or siRNA molecules. Modified dsRNA and siRNA molecules are particularly useful in these methods, as they are nuclease resistant, yet retain the biological activity of being able to inhibit viral replication by targeting an RNA sequence in a virus.

The invention further provides a method of making modified siRNAs that target a viral RNA or DNA sequence. The method comprises preparing a dsRNA fragment that contains at least one modified ribonucleotide in at least one strand, and cleaving the dsRNA fragment with Dicer enzyme, resulting in more than one modified siRNA.

Other objects, features and advantages of the invention will become apparent from the following detailed description. The description and specific examples indicate preferred embodiments, but should not be considered limiting, as various modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description. Further, the examples demonstrate the principle of the invention, but cannot be expected to specifically illustrate all useful applications.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts the sequence and secondary structure of the 5' UTR (SEQ ID NO:9) from the HCV genome. It also provides specific sequences of siRNAs for inducing RNAi toward HCV in hepatic cells (SEQ ID NOS:1-8, respectively, in order of appearance).

Fig. 2 provides sequences (SEQ ID NOS:10-66, respectively, in order by column) for several HCV-specific siRNAs that are useful for inducing RNAi toward HCV in hepatic cells. Each HCV-specific siRNA is identified by the designation provided in the first column.

Fig. 3 shows the nucleotide sequence (SEQ ID NO:67) of the SARS coronavirus.

Fig. 4 is a schematic representation of the open reading frames of the SARS coronavirus.

Fig. 5 depicts a subgenomic HCV replicon contained in the hepatoma cell line Huh 7, which was used to test the efficacy of siRNA in human liver cells.

Fig. 6 depicts the dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line), that were administered different concentrations of siRNA5. Luciferase activity, which was measured at 1, 2 and 3 days post-transfection, fell with increasing doses of siRNA. The luciferase assay was performed using a Luciferase assay system available from Promega Corp. (Madison, WI), according to the manufacturer's instructions.

Fig. 7 depicts the sequence specificity of siRNA5 for inducing HCV-directed RNAi in Huh-7 liver cells.

Fig. 8 demonstrates that siRNA5 is not toxic to Huh-7 cells. ATPase levels were assayed using an ATPase assay kit available from Promega Corp. (Madison, WI), according to the manufacturer's instructions.

Fig. 9 depicts the effects of siRNA5 on HCV replication in 21-5 cells (Huh-7 cells containing full-length HCV), as measured by RNA assay. RNA levels were assayed using a TaqMan™ RNA kit (F. Hoffman La-Roche, Switzerland), according to the manufacturer's instructions. Values are normalized.

Fig. 10 demonstrates that siRNA5 does not affect the viability of Huh 5-2 cells. Specifically, mRNA encoding GAPDH, an enzyme essential to glycolysis was measured in Huh 5-2 cells transfected with siRNA5 or GAPDH-specific siRNA. The graph demonstrates that siRNA5 did not affect RNA levels of GAPDH. GAPDH was measured using a TaqMan™ RNA kit (F. Hoffman La-Roche, Switzerland), according to the manufacturer's instructions. Values are normalized.

Fig. 11 depicts a dose response of normalized luciferase activity in Huh 7 cells containing a subgenomic HCV replicon (5-2 line) that were administered different concentrations of 2'-fluoro-siRNA (2'-F-GL2), which targets the fruit fly luciferase gene. Luciferase activity, which was measured at 2 days post-transfection, fell with

increasing doses of siRNA. The luciferase assay was performed using a Firefly Luciferase kit (Promega Corp., Madison, WI), according to the manufacturer's instructions.

Fig. 12 demonstrates an inhibition of luciferase activity in 5-2 cells using the siRNA Chol-GL2 in the absence of liposomes.

Fig. 13 depicts an autoradiograph of 5'-labeled siRNA duplexes separated by PAGE, and shows the stability of 2'-fluoro-modified siRNA (2'-F-GL2) incubated in human serum for up to 10 days. The siRNA duplexes were subjected to incubation with human serum and analysis by 20% PAGE. The composition of the lanes is as follows: Lanes 1, 11 and 21: ³²P-end labeled siRNA alone; Lanes 2-10, 12-20 and 22-25: siRNA incubated with human serum. Lanes 2 & 12, 1 min ; Lanes 3 & 13, 5 min ; Lanes 4 & 14, 15 min ; Lanes 5 & 15, 30 min ; Lanes 6 & 16, 1 hr ; Lanes 7 & 17, 2 hr ; Lanes 8 & 18, 4 hr ; Lanes 9 & 19, 8 hr ; Lanes 10 & 20, 24 hr ; Lanes 22, 24 hr ; Lanes 23, 48 hr ; Lanes 24, 120 hr ; Lanes 25, 240 hr incubation, respectively.

Fig. 14 demonstrates the use of recombinant human dicer to convert fluorinated dsRNA into 2'-F-siRNA. The composition of the lanes is as follows: Lane 1: size marker, λ HindIII+ ϕ X174/HaeIII; Lane 2: ribo/ribo homoduplex RNA; Lane 3: ribo/2'-F heteroduplex RNA; Lane 4: 2'-F/ribo heteroduplex RNA; Lane 6: size marker, 10bp DNA ladder; Lane 7: ribo/ribo homoduplex siRNA; Lane 8: ribo/2'-F heteroduplex siRNA; Lane 9: 2'-F/ribo heteroduplex siRNA; Lane 10: 2'-F/2'-F homoduplex siRNA.

Fig. 15 shows a dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line) to HCV-specific siRNAs. Luciferase activity fell with increasing doses of each siRNA.

Fig. 16 shows that cholesterol shows a dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line) to cholesterol-modified GL2 siRNA.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides dsRNA molecules that are about 10 to about 30 nucleotides long, and that mediate RNA interference in target cells. Preferably, the inventive molecules are chemically modified to confer increased stability against nuclease degradation, but retain the ability to bind to target nucleic acids.

As used herein, “RNA interference” (RNAi) refers to sequence-specific or gene specific suppression of gene expression (protein synthesis) that is mediated by siRNA, without generalized suppression of protein synthesis. While the invention is not limited to a particular theory or mode of action, RNAi may involve degradation of messenger RNA (mRNA) by an RNA-induced silencing complex (RISC), preventing translation of the transcribed mRNA. Alternatively, it may involve methylation of genomic DNA, which shunts transcription of a gene. The suppression of gene expression caused by RNAi may be transient or it may be more stable, even permanent.

“Gene suppression”, “targeted suppression”, “sequence-specific suppression”, “targeted RNAi” and “sequence-specific RNAi” are used interchangeably herein. Furthermore, sequence-specific suppression, as used herein, is determined by separately assaying levels of the protein targeted for suppression in cells containing the siRNA (experimental cells) and in cells not containing the identical siRNA (control cells), then comparing the two values. Experimental and control cells should be derived from the same source and same animal. Also, control and experimental cells used in determining the level or quantity of gene suppression should be assayed under similar, if not identical, conditions.

RNA is a polymer of ribonucleotides, each containing the sugar ribose in association with a phosphate group and a nitrogenous base (typically, adenine, guanine, cytosine, or uracil). Like its cousin, DNA, RNA can form complementary hydrogen bonds. Therefore, RNA may be double-stranded (dsRNA), single-stranded (ssRNA) or double-stranded with a single-stranded overhang. Common types of RNA include messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), micro RNA (miRNA) and small hairpin

RNA (shRNA), each of which plays a specific role in biological cells. As used herein, the term “RNA” includes all of these.

“Small interfering RNA” (siRNA) refers to double-stranded RNA molecules from about 10 to about 30 nucleotides long that are named for their ability to specifically interfere with protein expression. Preferably, siRNA molecules are 12-28 nucleotides long, more preferably 15-25 nucleotides long, still more preferably 19-23 nucleotides long and most preferably 21-23 nucleotides long. Therefore, preferred siRNA molecules are 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 28 or 29 nucleotides in length.

The length of one strand designates the length of an siRNA molecule. For instance, an siRNA that is described as 21 ribonucleotides long (a 21-mer) could comprise two opposite strands of RNA that anneal together for 19 contiguous base pairings. The two remaining ribonucleotides on each strand would form an “overhang.” When an siRNA contains two strands of different lengths, the longer of the strands designates the length of the siRNA. For instance, a dsRNA containing one strand that is 21 nucleotides long and a second strand that is 20 nucleotides long, constitutes a 21-mer.

siRNAs that comprise an overhang are desirable. The overhang may be at the 5' or the 3' end of a strand. Preferably, it is at the 3' end of the RNA strand. The length of an overhang may vary, but preferably is about 1 to about 5 bases, and more preferably is about 2 nucleotides long. Preferably, the siRNA of the present invention will comprise a 3' overhang of about 2 to 4 bases. More preferably, the 3' overhang is 2 ribonucleotides long. Even more preferably, the 2 ribonucleotides comprising the 3' overhang are uridine (U).

siRNAs of the present invention are designed to interact with a target ribonucleotide sequence, meaning they complement a target sequence sufficiently to bind to the target sequence. Preferably the target ribonucleotide sequence derives from a disease producing agent or pathogen. More preferably, the target ribonucleotide sequence is in a virus genome of an RNA virus or a DNA virus. Even more preferably, the virus is selected from the group consisting of hepatitis C virus

(HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus.

Hepatitis C virus (HCV) is a highly preferred virus target. Figure 1 and Figure 2 disclose the nucleic acid sequences for several HCV-specific siRNA molecules. Among those shown, siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, and siRNA5B4 have shown particularly good activity, and therefore are highly preferred. siRNAs at least 80%, 90%, or 95%, identical to these highly preferred siRNAs also constitute part of the invention..

Another preferred virus target is the coronavirus, which is associated with upper respiratory infections in humans and recently has been linked with SARS (severe acute respiratory syndrome). Coronavirus has the largest known RNA virus genome, 32 kilobases long, and its genome is composed of positively stranded RNA. (See Figure 5) Each coronavirus mRNA has a 5'-end leader sequence of 60 to 80 nucleotides that is identical to the 5'-UTR of genomic RNA approximately 200 nucleotides long. (See Figure 6) These sequences are highly conserved, and therefore, provide an excellent source of target sequences for which siRNAs. See Fundamental Virology, 3rd Ed., Chapter 18, p. 541-560 (Eds. Fields, Knipe and Howley), Lippincott-Raven (1995). In one embodiment, the entire leader sequence (nucleotides 1-72) is targeted. In another embodiment, one or more sections of the leader sequence is targeted. In a preferred embodiment, nucleotides 64-72 (TAAACGAAC) of the leader sequence are targeted. siRNA targeted to the coronavirus may be modified or unmodified.

In one embodiment, the invention provides an siRNA molecule comprising a ribonucleotide sequence at least 80% identical to a ribonucleotide sequence from a target agent or virus. Preferably, the siRNA molecule is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the ribonucleotide sequence of the target agent or virus. The target can be the entire viral genome, a primary transcript, an open reading frame, or any portion of these. Most preferably, an siRNA will be 100% identical to the nucleotide sequence of a target agent or virus. However, siRNA molecules with insertions, deletions or single point mutations relative to a target may

also be effective. Tools to assist siRNA design are readily available to the public. For example, a computer-based siRNA design tool is available on the internet at www.dharmacon.com.

By way of example, a polynucleotide having a nucleotide sequence at least 95% "identical" to a reference nucleotide sequence means that the polynucleotide's sequence may include up to five point mutations per 100 nucleotides of the reference nucleotide sequence, or 1 point mutation per 20 nucleotides. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular nucleic acid molecule is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the ribonucleotide sequence of a target agent or virus can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, Madison, WI). Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2:482-489 (1981)) to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference ribonucleotide sequence and that gaps in homology of up to 5% of the total number of ribonucleotides in the reference sequence are allowed.

The present invention also includes siRNA molecules that have been chemically modified to confer increased stability against nuclease degradation, but retain the ability to bind to target nucleic acids that may be present in cells. In the

case where a target RNA is virus-specific, the modified siRNAs are able to bind to the virus specific RNAs or DNAs, thereby inactivating the virus.

A modified siRNA of the present invention comprises a modified ribonucleotide, and is resistant to enzymatic degradation, such as RNase degradation, yet retains the ability to inhibit viral replication in a cell containing the specific viral target RNA or DNA sequences. The siRNA may be modified at any position of the molecule so long as the modified siRNA binds to a target sequence and is resistant to enzymatic degradation. Modifications in the siRNA may be in the nucleotide base, *i.e.*, the purine or the pyrimidine, the ribose or the phosphate. Preferably, the modification occurs at the 2' position of at least one ribose in an siRNA.

More specifically, the siRNA is modified in at least one pyrimidine, at least one purine or a combination thereof. However, generally all pyrimidines (cytosine or uracil), or all purines (adenosine or guanine) or a combination of all pyrimidines and all purines of the siRNA are modified. More preferably, the pyrimidines are modified, and these pyrimidines are cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. Ribonucleotides on either one or both strands of the siRNA may be modified.

Ribonucleotides containing pyrimidine bases found in RNA (cytidine and uridine) can be chemically modified by adding any molecule that inhibits RNA degradation or breakdown of the base, the ribose or the phosphates. As previously noted, the 2' position of ribose is a preferred site for modification. 2' modified siRNAs have a longer serum half-life and are resistant to degradation, relative to unmodified siRNAs or single-stranded RNAs, such as antisense or ribozyme. 2'-modified pyrimidine ribonucleotides can be formed by a number of different methods known in the art.

A preferable chemical modification is the addition of a molecule from the halide chemical group to a ribonucleotide of siRNA. Within the halides, fluorine is a preferred molecule. Besides fluoro-, other chemical moieties such as methyl-, methoxyethyl- and propyl- may be added as modifications. The most preferred

modification, though, is fluoro-modification, such as a 2'-fluoro-modification or a 2',2'-fluoro-modification.

Thus, in a preferred embodiment of the invention, siRNA is modified by the addition of a fluorine molecule to the 2' carbon of a pyrimidine ribonucleotide. The siRNA may be fluorinated completely or partially. For example, only the cytosine ribonucleotides may be fluorinated. Alternatively, only the uracil ribonucleotides may be fluorinated. In a preferred embodiment, both uracil and cytosine are fluorinated. Only one strand, either sense or antisense, of siRNA may to be fluorinated. Even partial 2' fluorination of siRNA gives protection against nucleolytic degradation. Importantly, 2' fluorinated siRNA is not toxic to cells, an unexpected result given that fluorine chemistry usually is toxic to living organisms.

In addition, modified siRNAs of the present invention may contain chemical modifications that inhibit viral RNA polymerases. For example, siRNAs may comprise one or more nucleosides that inhibit viral RNA-dependent RNA polymerases. Examples of such nucleosides and other chemical modifications exist in WO 02/057425, WO 02/057287, WO 02/18404, WO 02/100415, WO 02/32920, WO 01/90121, US patent No. 6,063,628 and US published application No. 2002/0019363.

siRNA can be prepared in a number of ways, such as by chemical synthesis, T7 polymerase transcription, or by treating long double stranded RNA (dsRNA) prepared by one of the two previous methods with Dicer enzyme. Dicer enzyme creates mixed populations of dsRNA from about 21 to about 23 base pairs in length from dsRNA that is about 500 base pairs to about 1000 base pairs in size. Unexpectedly, Dicer can effectively cleave modified strands of dsRNA, such as 2' fluoro-modified dsRNA. Before development of this method, it was previously thought that Dicer would not be able to cleave modified siRNA. The Dicer method of preparing siRNAs can be performed using a Dicer siRNA Generation Kit available from Gene Therapy Systems (San Diego, CA).

The invention particularly includes a method of making a modified siRNA that targets a nucleic acid sequence in a virus, comprising (a) preparing a modified-double stranded RNA (dsRNA) fragment containing at least one modified

ribonucleotide in at least one strand, and (b) cleaving the modified-dsRNA fragments with recombinant human Dicer, resulting in more than one modified siRNA. The method may further comprise (c) isolating the modified siRNAs.

In the methods for making siRNA, a dsRNA fragment can be prepared by chemical synthesis or in vitro translation. In one embodiment, the modified siRNA is a 2' modified siRNA in which the modification is at the 2' position of at least one ribonucleotide of said siRNA. The modification is selected from the group consisting of fluoro-, methyl-, methoxyethyl and propyl-modification. Preferably the fluoro-modification is a 2'-fluoro-modification or a 2',2'-fluoro-modification. The pyrimidines, the purines or a combination thereof of the siRNA are modified. More preferably, the pyrimidines are modified, such as cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. One or both strands of the siRNA may contain one or more modified ribonucleotide.

The invention further provides a method of inactivating a target agent or virus in a patient by administering to the patient a dsRNA in an effective amount to inactivate the targeted agent or virus. Preferably the dsRNA is modified as described above. RNA interference toward a targeted DNA segment in a cell can be achieved by administering a double-stranded RNA molecule to the cells, wherein the ribonucleotide sequence of the double-stranded RNA molecule corresponds to the ribonucleotide sequence of the targeted DNA segment. Preferably, the dsRNA used to induce targeted RNAi is siRNA.

As used herein "targeted DNA segment" is used to mean a DNA sequence encoding, in whole or in part, an mRNA for a targeted protein, including introns or exons, where suppression is desired. DNA segment can also mean a DNA sequence that normally regulates expression of the targeted protein, including but not limited to the promoter of the targeted protein. Furthermore, the DNA segment may or may not be a part of the cell's genome or it may be extrachromosomal, such as plasmid DNA.

The present invention is particularly directed to a method of inactivating a virus in a patient by administering to the patient an siRNA, preferably a modified siRNA, in an effective amount to inactivate the virus. The siRNA is preferably about

10 to about 30 ribonucleotides in length, more preferably 12-28 ribonucleotides, more preferably 15-25 ribonucleotides, even more preferably 19 –23 ribonucleotides and most preferably 21-23 ribonucleotides.

Also, the method of inactivating a virus preferably utilizes an siRNA that is modified at the 2' position of at least one ribonucleotide of said siRNA. The siRNA may be modified with chemical groups selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-. Fluoro-modification is most preferred, and either a 2'-fluoro-modification or a 2',2'-fluoro-modification is useful in the method. The modification may be at a pyrimidine, a purine or a combination thereof of the siRNA. More preferably the pyrimidines are modified, such as cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. In one embodiment, one strand of the siRNA contains at least one modified ribonucleotide, while in another embodiment, both strands of the siRNA contain at least one modified ribonucleotide.

siRNAs useful in treatment methods may also be modified by the attachment of at least one, but preferably more than one, receptor-binding ligand(s) to the siRNA. Such ligands are useful to direct delivery of siRNA to a target virus in a body system, organ, tissue or cells of a patient, such as the liver, gastrointestinal tract, respiratory tract, the cervix or the skin.

In preferred embodiments, receptor-binding ligands are attached to either a 5'-end or a 3'-end of an siRNA molecule. Receptor-binding ligands may be attached to one or more siRNA ends, including any combination of 5'- and 3'-ends. Thus, when receptor binding ligands are attached only to the ends of an siRNA molecule, anywhere between 1 and 4 such ligands may be attached.

The selection of an appropriate ligand for targeting siRNAs to viruses in particular body systems, organs, tissues or cells is considered to be within the ordinary skill of the art. For example, to target an siRNA to hepatocytes, cholesterol may be attached at one or more ends, including any combination of 5'- and 3'-ends, of an siRNA molecule. The resultant cholesterol-siRNA is delivered to hepatocytes in the liver, thereby providing a means to deliver siRNAs to this targeted location. Other

ligands useful for targeting siRNAs to the liver include HBV surface antigen and low-density lipoprotein (LDL).

As another example, siRNA molecules that target Human Immunodeficiency virus type 1 (HIV-1) can be delivered to T lymphocytes where the target nucleic acids are located (Song, E. *et al.*, *J. of Virology*, 77(13): 7174-7181 (2003)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, HIV-1 surface antigen capable of binding to the CD4 surface protein located on T-cells (Kilby, M. *et al.*, *New England J. of Medicine*, 348(22): 2228-38 (2003)).

Similarly, siRNA molecules that target Influenza A virus can be delivered to epithelial cells of the respiratory tract where the target nucleic acids are located (Ge, Q. *et al.*, *Proc. Natl. Acad. of Sciences*, 100(5): 2718-2723 (2002)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, the Influenza virus surface antigen, which is capable of binding to the sialic acid residues located on the surface of the epithelial cells (Ohuchi, M., *et al.*, *J. of Virology*, 76(24): 12405-12413 (2002); Glick, G. *et al.*, *J. of Biol. Chem.*, 266 (35): 23660-23669 (1991)).

Also, siRNA molecules that target respiratory syncytial virus (RSV) can be delivered to epithelial cells of the respiratory tract where the target nucleic acids are located (Bitko, V. *et al.*, *BMC Microbiology*, 1:34 (2001)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, RSV surface antigen (Malhotra, R. *et al.*, *Microbes and Infection*, 5: 123-133 (2003)).

As still another example, siRNAs that target Human Papillomavirus (HPV) can be delivered to basal epithelial cells where the target nucleic acids are located (Hall, A. *et al.*, *J. of Virology*, 77(10): 6066-6069 (2003)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, HPV surface antigen capable of binding to heparin sulfate proteoglycans located on the surface of basal epithelial cells (Bousarghin L. *et al.*, *J. of Virology*, 77(6): 3846-3850 (2002)).

Further, siRNAs that target Poliovirus (PV) can be delivered to cells of the nervous system where the target nucleic acids are located (Gitlin, L. *et al.*, *Nature*,

418: 430-434 (2002)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, PV surface antigen capable of binding to the CD155 receptor located on the surface of neurons (He, Y. *et al.*, *Proc. Natl. Acad. of Sciences*, 97 (1): 79-84 (2000)).

As noted, the methods of treatment are intended to target disease-causing agents or pathogens, and more particularly viruses, which can be either RNA viruses or DNA viruses. Preferred viruses are selected from the group consisting of hepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus. More preferably the target virus is hepatitis C virus or a coronavirus.

In one aspect, the method utilizes an siRNA prepared by (a) identifying a target ribonucleotide sequence in a virus genome for designing a small interfering RNA (siRNA) and (b) producing a siRNA that has been modified to contain at least one modified ribonucleotide. Preferably, the siRNA comprises a double-stranded RNA molecule with a first strand ribonucleotide sequence corresponding to a ribonucleotide sequence corresponding to a target ribonucleotide sequence in the virus, and a second strand comprising a ribonucleotide sequence complementary to the target ribonucleotide sequence. The first and second strands should be separate complementary strands that hybridize to each other to form a double-stranded RNA molecule. Moreover, one or both of the strands should comprise at least one modified ribonucleotide.

In preferred embodiments of the invention, the siRNA targets a ribonucleotide sequence in the hepatitis C virus genome. The target ribonucleotide sequence comprises a conserved ribonucleotide sequence necessary for HCV replication, and the conserved ribonucleotide sequence is selected from the group consisting of 5'-untranslated region (5'-UTR), 3'-untranslated region (3'-UTR), core, and NS3 helicase. Highly preferred siRNA molecules comprise a sequence at least 80% identical to those of siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, or siRNA5B4. The siRNAs may be unmodified, or modified as described above.

Methods of inhibiting the replication of HCV in cells positive for HCV should not be toxic to the cells, or cause apoptosis in the treated cells. Preferably, the inhibition of HCV replication is specifically tailored to affect only HCV replication in the cells, such that normal growth, division or metabolism is not affected. Cells in which HCV has been shown to replicate include, but are not limited to hepatic cells, B cell lymphocytes and T cell lymphocytes. Preferably, a method of inhibiting the replication of HCV is performed in hepatic cells.

According to the invention, "hepatic cells" can be from any animal source. Further, the hepatic cells may be in cell culture, or part of a tissue, or an organ, in part or in whole. The phrase hepatic cells is meant to include any cell constituting a normal, abnormal or diseased liver cell. Examples of hepatic cells include, but are not limited to, Kupffer cells, hepatocytes and cells comprising a hepatocellular carcinoma. "Hepatic cells" is not meant to include cells that make up discrete structures within the liver, such as endothelial cells lining blood vessels. A tissue or organ containing the hepatic cells may be within a subject or may be biopsied or removed from the animal. Additionally, the tissue may be "fresh" in that the tissue would be recently removed from a subject, without any preservation steps between the excision and the methods of the current invention. Prior to application of the methods of the current invention, the tissue may also have been preserved by such standard tissue preparation techniques including, but not limited to, freezing, quick freezing, paraffin embedding and tissue fixation. Furthermore, the tissue may also be a xenograft or a syngraft on or in another host animal. As used herein, the terms animal and subject are used interchangeably.

According to the invention, "hepatitis C virus," or "HCV," takes its ordinary meaning in the art as of the date of invention. The hepatitis C virus is an RNA virus of the *Flaviviridae* family. For example as used herein, HCV includes, but is not limited to genotypes 1-11 (using the most common genotyping system), with these genotypes being broken down into sub-types, some of which include but are not limited to 1a, 1b, 1c, 2a, 2b, 2c, 3a, 3b, 4a, 4b, 4c, 4d, 4e, 5a, 6a, 7a, 7b, 8a, 8b, 9a, 10a and 11a. Further, isolates from individuals consist of closely related yet heterogeneous populations of viral genomes, sometimes referred to as quasispecies.

Pestivirus is yet another target of the present invention. As used herein, "pestivirus" takes its ordinary meaning in the art as of the date of invention. The pestivirus belongs to the family *Flaviviridae*. Pestivirus is widespread throughout the Australian cattle population. It is believed that about 70% of herds are actively infected with pestivirus. Infection of susceptible animals can cause a variety of diseases - some not apparent until well after the initial spread of the virus into a herd. Pestivirus is a genus of viruses that includes hog cholera virus, bovine viral diarrhea virus (BVDV) and border disease virus (BDV) or hairy-shaker disease virus.

siRNA may be administered to a patient by intravenous injection, subcutaneous injection, oral delivery, liposome delivery or intranasal delivery. The siRNA may then accumulate in a target body system, organ, tissue or cell type of the patient.

The present invention also provides a method of inhibiting the replication of a virus in mammalian cells, comprising transfecting cells harboring the virus with a vector that directs the expression of virus-specific siRNA. In one embodiment, the invention provides a method of inhibiting the replication of hepatitis C virus (HCV) in cells positive for HCV, comprising transfecting HCV-positive cells with a vector that directs the expression of an HCV-specific siRNA. The cells may be evaluated to determine if a marker in the cells has been inhibited by the siRNA.

Thus, the invention also provides vectors and host cells comprising a nucleic acid segment encoding the described siRNAs.

Vectors of the present invention may be employed for producing siRNAs by recombinant techniques. Thus, for example, a DNA segment encoding an siRNA may be included in any one of a variety of expression vectors for expressing any DNA sequence. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in a desired host.

The appropriate DNA segment may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA segment in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct siRNA synthesis. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous Sarcoma Virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter. Preferably the promoters of the present invention are from the type III class of RNA polymerase III promoters. More preferably, the promoters are selected from the group consisting of the U6 and H1 promoters. The U6 and H1 promoters are both members of the type III class of RNA polymerase III promoters. The promoters of the present invention may also be inducible, in that expression may be turned "on" or "off." For example, a tetracycline-regulatable system employing the U6 promoter may be used to control the production of siRNA. The expression vector may or may not contain a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or tetracycline or ampicillin resistance.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader

sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

In one embodiment, the invention provides a vector, wherein the DNA segment encoding the sense strand of the RNA polynucleotide is operably linked to a first promoter and where the DNA segment encoding the antisense (opposite) strand of the RNA polynucleotide molecule is operably linked to a second promoter. In other words, each strand of the RNA polynucleotide is independently expressed. Furthermore, the promoter driving expression of each strand can be identical or each one may be different from the other promoter.

In another embodiment, the vector of the current invention may comprise opposing promoters. For example, the vector may comprise two U6 promoters on either side of the DNA segment encoding the sense strand of the RNA polynucleotide and placed in opposing orientations, with or without a transcription terminator placed between the two opposing promoters. The U6 opposing promoter construct is similar to the T7 opposing promoter construct as described in Wang, Z. *et al.*, J. Biol. Chem. 275: 40174-40179 (2000). See Miyagishi, M. and Taira, K., Nature Biotech. 20: 497-500 (2002).

In another embodiment, the DNA segments encoding both strands of the RNA polynucleotide are under the control of a single promoter. In one embodiment, the DNA segments encoding each strand are arranged on the vector with a "loop" region interspersed between the two DNA segments, where transcription of the DNA segments and loop region creates one RNA transcript. The single transcript will, in turn, anneal to itself creating a "hairpin" RNA structure capable of inducing RNAi. The "loop" of the hairpin structure is preferably from about 4 to about 6 nucleotides in length. More preferably, the loop is 4 nucleotides in length.

The vector containing the appropriate DNA sequence as described herein, as well as an appropriate promoter or control sequence, may be employed to transform

an appropriate host to permit the host to express the siRNA. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, N.Y. (1989).

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, cloning vectors or expression vectors. The vectors may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells may be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

In a further embodiment, the present invention relates to host cells containing the above-described constructs. A host cell may be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell may be a prokaryotic cell, such as a bacterial cell. Preferably, host cells are mammalian cells. More preferably, host cells are hepatic cells. Introduction of a construct into host cells can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., et al., *Basic Methods in Molecular Biology* (1986)).

The term patient, as used herein, refers to an animal, preferably a mammal. More preferably the patient can be a primate, including non-human and humans. The terms subject and patient are used interchangeably herein.

The treatments envisioned by the current invention can be used for subjects with a pre-existing viral infection, or for subjects pre-disposed to an infection. Additionally, the methods of the current invention can be used to correct or compensate for cellular or physiological abnormalities involved in conferring susceptibility to viral infections in patients, and/or to alleviate symptoms of a viral infections in patients, or as a preventative measure in patients.

The method of treating a patient having a viral infection involves administration of compositions to the subjects. As used herein, composition can mean a pure compound, agent or substance or a mixture of two or more compounds, agents or substances. As used herein, the term agent, substance or compound is intended to mean a protein, nucleic acid, carbohydrate, lipid, polymer or a small molecule, such as a drug.

In one embodiment of the current invention, the composition administered to the subject is a pharmaceutical composition. Further, the pharmaceutical composition can be administered orally, nasally, parenterally, intrasystemically, intraperitoneally, topically (as by drops or transdermal patch), buccally, or as an oral or nasal spray. Intranasal delivery of a virus that causes upper respiratory diseases, such as the coronavirus or the metapneumovirus, would be a particularly advantageous delivery mode. The term "parenteral," as used herein, refers to modes of administration that include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. The pharmaceutical compositions as contemplated by the current invention may also include a pharmaceutically acceptable carrier.

"Pharmaceutically acceptable carrier" includes, but is not limited to, a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type, such as liposomes.

A pharmaceutical composition of the present invention for parenteral injection can comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The compositions of the present invention can also contain adjuvants such as, but not limited to, preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorb acid, and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, to prolong the effect of the drugs, it is desirable to slow the absorption from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, can depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compounds are mixed with at least one item pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders

such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form can also comprise buffering agents.

Solid compositions of a similar type can also be employed as fillers in soft and hard filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms can contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive,

castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, can contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Alternatively, the composition can be pressurized and contain a compressed gas, such as nitrogen or a liquefied gas propellant. The liquefied propellant medium and indeed the total composition is preferably such that the active ingredients do not dissolve therein to any substantial extent. The pressurized composition can also contain a surface active agent. The surface active agent can be a liquid or solid non-ionic surface active agent or can be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.

The compositions of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the compounds of the invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art (*see, for example, Prescott, Ed., Meth. Cell Biol. 14:33 et seq (1976)*).

One of ordinary skill in the art will appreciate that effective amounts of the agents of the invention can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form. A "therapeutically effective" amount of the inventive compositions can be

determined by prevention or amelioration of adverse conditions or symptoms of diseases, injuries or disorders being treated. The agents can be administered to a subject, in need of treatment of viral infection, as pharmaceutical compositions in combination with one or more pharmaceutically acceptable excipients. It will be understood that, when administered to a human patient, the total daily usage of the agents or composition of the present invention will be decided by the attending physician within the scope of sound medical judgement. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the agents at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosages until the desired effect is achieved.

Dosing also can be arranged in a patient specific manner to provide a predetermined concentration of the agents in the blood, as determined by techniques accepted and routine in the art. Thus patient dosaging can be adjusted to achieve regular on-going blood levels, as measured by HPLC, on the order of from 50 to 1000 ng/ml.

It will be readily apparent to one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein can be made without departing from the scope of the invention or any embodiment thereof.

EXAMPLES

The examples demonstrate that siRNA, including modified siRNA, can effectively inhibit viral replication in mammalian cells. Moreover, the examples

show that the inventive siRNAs promote HCV RNA degradation in human liver cells and establish that hepatocytes possess the necessary functional components of modified siRNA-induced silencing. The examples also demonstrate that siRNA technology can be used as a therapy to inhibit HCV replication in host cells. The inventors, by submitting the following examples, do not intend to limit the scope of the claimed invention.

EXAMPLE 1

To test whether siRNA directed to the HCV genome confers intracellular immunity against this human pathogen, a recently developed HCV cell culture systems in human hepatoma cell line, Huh-7, was used. One of the cell lines, 5-2, harbors autonomously replicating subgenomic HCV RNA (Bartenschlager, J. Virol, 2001). The subgenomic replicon carries firefly luciferase gene, allowing a reporter function assay as a measure of HCV RNA replication (Fig. 5). Owing to cell culture adaptive mutations introduced into the genome (Bart), these 5-2 cells replicate HCV RNA at levels of up to 5×10^4 virus particles/cell.

Using T7 transcription, several 21-bp siRNA duplexes against different regions of the 5'-UTR of the HCV genome were made (Fig 5). Briefly, 2 oligo double-stranded DNA molecules comprising the T7 promoter and the 5' UTR of HCV being oriented in either the sense direction or the antisense direction were generated. Each oligo DNA was then transcribed *in vitro* to produce (+) and (-) RNA and then treated with DNAase I to remove the DNA template. The two RNA strands were allowed to anneal at 37°C overnight, generating dsRNA. After treating the dsRNA with RNAase T1 to remove unreacted ssRNA species, the dsRNA was purified for transfection.

Several other siRNA duplexes were designed, including GL2 and GL3, that were directed against the fruit fly and sea pansy luciferase genes, respectively. Using standard transfection techniques, the siRNAs were transfected into the 5-2 cells and luciferase activity was measured to determine the effect of the siRNAs on HCV replication. Luciferase activity was measured 48 hours after transfection. In cells

where siRNA5 was transfected, there was reduced luciferase activity of up to 85%, in a dose responsive manner (Fig. 6). The inhibition of luciferase activity was not seen in cells that were transfected with irrelevant siRNA (SIN). The sequence of SIN was taken from sindbis virus transcription promoter (Fig. 1).

EXAMPLE 2

The sequence specificity of the siRNA5 response was further tested using additional siRNA duplexes, GL2 and GL3. Figure 1 shows that GL2 and GL3 differ from each other by 3-nucleotides. Luciferase activity was reduced by 90% in cells transfected with siRNA5 or GL2, but no significant reduction was seen in cells transfected with GL3 (Fig. 7). The luciferase assay was performed using a Luciferase assay system available from Promega Corp. (Madison, WI), according to the manufacturer's instructions.

EXAMPLE 3

Whether or not siRNA5 was toxic to transfected cells also was tested. Toxicity was by measured using an ATPase activity assay. Figure 8 shows that the siRNA5-induced reduction in HCV replication, as seen in Figure 6, was not due to cellular toxicity which is attributed to non sequence-specific RNAi. ATPase levels were assayed using an ATPase assay kit from Promega (Madison, WI) according to the manufacturer's instructions.

EXAMPLE 4

The full-length HCV replicon may possess the ability to adapt and suppress RNAi, thus replicating in spite of the presence of siRNA, as documented in Li, H, Science 296:1319-1321 (2002). To determine the effects of siRNA5 on replication of full-length HCV RNA in Huh-7 cells, from the 21-5 cell line, harboring the selectable full-length HCV replicon, were treated with siRNA5. Levels of HCV RNA were measured by quantitative PCR using TaqMan™ (F. Hoffman La-Roche, Switzerland). The results as seen in Figure 9 show that siRNA-directed silencing reduced steady-

state viral RNA production, even in the setting of an adapted HCV mutant, where RNA replication was very high. Results from both subgenomic and full-length HCV replicons suggest that none of the HCV proteins can suppress RNA interference.

EXAMPLE 5

Whether or not siRNA5 was toxic to transfected cells also was tested. Specifically, mRNA encoding GAPDH, an enzyme essential in glycolysis, was measured in Huh 5-2 cells transfected with siRNA5, or siRNA specific towards the GAPDH sequence. Figure 10 demonstrates that siRNA5 did not affect RNA levels of GAPDH. GAPDH was measured using a TaqMan™ RNA kit (F. Hoffman La-Roche, Switzerland) according to the manufacturer's instructions.

EXAMPLE 6

To test the effectiveness of siRNA5 on inhibiting the ability of HCV to replicate in an infected liver, portions of HCV-infected human liver are xenografted onto transgenic severe combined immunodeficient (SCID) mice according to methods well known to the skilled artisan.

Briefly, once the HCV-infected liver has supplanted the mouse liver, liposome-encapsulated siRNA5, or control liposomes are administered by intravenous injection to the mice through the tail vein, or another accessible vein. The mice are dosed one time a day for 3-10 days.

At the end of the dosing regimen the mice are sacrificed and blood collected and the livers removed. The liver is divided into portions such that a portion is frozen using liquid nitrogen, a portion is fixed for paraffin embedding, and a portion is fixed for sectioning onto slides.

Using the appropriate allotment, HCV RNA is quantified using the TaqMan™ RNA assay kit previously utilized herein to determine the levels of HCV RNA in the liver cells. Further, anti-HCV antibody titers can be measured in the collected blood samples, along with serum ALT levels.

EXAMPLE 7

To test the effectiveness of siRNA5 on inhibiting the ability of HCV to infect a healthy liver, portions of normal human liver are xenografted onto transgenic severe combined immunodeficient (SCID) mice according to methods well known to the skilled artisan.

Briefly, once the healthy liver has supplanted the mouse liver, liposome-encapsulated siRNA5, or control liposomes are administered by intravenous injection to the mice through the tail vein, or another accessible vein. The mice are dosed one time a day for 3-10 days. After the pre-dosing regimen, active HCV is then injected intravenously, or via hepatic injection, into the mice.

At about 6, 12, 18, 24 hours, and periodically up to about 5 days after the mice are infected with HCV, the mice are sacrificed and blood collected and the livers removed. The liver is divided into portions such that a portion is frozen using liquid nitrogen, a portion is fixed for paraffin embedding, and a portion is fixed for sectioning onto slides.

Using the appropriate allotment, HCV RNA is quantified using the TaqMan™ RNA assay kit previously utilized herein to determine the levels of HCV RNA in the liver cells. Further, anti-HCV antibody titers can be measured in the collected blood samples, along with serum ALT levels.

EXAMPLE 8

Modified siRNA can be prepared by chemical synthesis. In one embodiment, each C and U within a siRNA duplex, *e.g.* GL2, can be substituted with 2'-F-U and 2'-F-C. To produce siRNA with 3'-end overhangs comprising 2'-F-U and 2'-F-C, a universal support can be used. By selectively cleaving the oligo from the support, a practitioner can ensure that residues of the overhangs comprise modified nucleotides. Alternatively, the nucleotides comprising the 3'-end overhang can be unmodified dTdT.

2'-F RNA oligonucleotides can be synthesized on an Applied Biosystems 8909 or 8905 DNA/RNA synthesizer using the standard 1 μ mol beta-cyanoethyl phosphoramidite RNA chemistry protocol. The RNA phosphoramidite monomers and columns of Pac-A, 2'-F-Ac-C, iPr-Pac-G, 2'-F-U, and U-RNA CPG can be obtained from Glen Research (Sterling, VA). (See catalog nos. 10-3000-05, 10-3415-02, 10-3021-05, 10-3430-02, and 20-3430-41E, respectively.) Glen Research's Sulfurizing Reagent (catalog no. 40-4036-10) can be used as an oxidant to obtain a single phosphorothioate backbone between the 3' CPG and a subsequent base. To attain the coupling, the oxidizing step of the standard RNA 1 μ mol protocol can be replaced with the standard thioate 1 μ mol protocol. Cholesteryl-TEG phosphoramidite (Glen Research, catalog no. 10-1975-90) and cholesteryl-TEG CPG (Glen Research, catalog no. 20-2975-41E) can be incorporated onto the 5' or 3' ends of one or more of the oligoribonucleotides. After synthesis, the 2'-F RNA's are cleaved and deprotected with 1:1 ammonium hydroxide/methylamine, and the silyl groups are removed with triethylamine trihydrofluoride using standard protocols. *See e.g.* http://www.glenres.com/productfiles/technical/tb_madeptection.pdf. The oligoribonucleotides are then desalted on Sephadex G25 columns (Pharmacia NAP 25, catalog no. 17-08252-02) with sterilized water and purified using standard gel electrophoresis protocols. Modified siRNAs also can be obtained from commercial vendors such as Dharmacon (Lafayette, CO).

Alternatively, modified siRNA can be prepared by transcription using the Durascribe™ T7 Transcription Kit purchased from Epicentre Technologies (Madison, WI).

The modified siRNAs (dsRNAs) made by these methods contain phosphodiester linked oligonucleotides. Standard methods for making modified single-stranded RNAs, such as antisense molecules, are useful for making modified siRNAs, as modified single-stranded RNAs can be annealed together to form double stranded RNAs. Such standard methods include, but are not limited to, those described in Chiang *et al.*, *J.Biol.Chem.* 266, 18162-18171 (1991); Baker *et al.*, *J.Biol.Chem.* 272, 11994-12000 (1997); Kawasaki *et al.*, *J.Med.Chem.* 36, 831-841 (1993); Monia *et al.*, *J.Biol.Chem.* 268, 14514-14522 (1993).

EXAMPLE 9

To test whether siRNA directed to the HCV genome confers intracellular immunity against this human pathogen, a recently developed HCV cell culture systems in human hepatoma cell line, Huh-7, was used. One of the cell lines, 5-2, harbors autonomously replicating subgenomic HCV RNA (Bartenschlager, J. Virol, 2001). The subgenomic replicon carries firefly luciferase gene, allowing a reporter function assay as a measure of HCV RNA replication. Owing to cell culture adaptive mutations introduced into the genome, 5-2 cells replicate HCV RNA at levels of up to 5×10^4 virus particles/cell.

Using T7 transcription, several 21-bp siRNA duplexes against different regions of the 5'-UTR of the HCV genome were made. Briefly, two oligo double-stranded DNA molecules comprising the T7 promoter and the 5' UTR of HCV being oriented in either the sense direction or the antisense direction were generated. Each oligo DNA was then transcribed *in vitro* to produce (+) and (-) RNA and then treated with DNAase I to remove the DNA template. The two RNA strands were allowed to anneal at 37°C overnight, generating dsRNA. After treating the dsRNA with RNAase T1 to remove the unreacted ssRNA species, the dsRNA was purified for transfection.

Two exemplary modified siRNAs are provided below:

Chol-GL2	Chol-CGUACGCGGAAUACUUCGAUU UUGCAUGCGCCUUAUGAAGCU
GL2	CGUACGCGGAAUACUUCGAUU UUGCAUGCGCCUUAUGAAGCU

Each C and U within siRNA GL2, directed against the fruit fly luciferase gene, was substituted with 2'-F-U and 2'-F-C. The modified siRNAs were transfected into the 5-2 cells using standard liposome transfection techniques. Specifically, the modified siRNAs were incubated for 4 hrs at 37°C in a 250 µl cell suspension containing 0.5 µl of Oligofectamine (Invitrogen, Carlsbad, CA), for 20 hrs in 375 µl serum containing culture medium, and for 24 hrs at 37°C in fresh medium without the

liposome-siRNA complex. Luciferase activity was measured 48 hours after transfection to determine the effect of the modified siRNAs on HCV replication.

Figure 11 shows that GL2 reduced the luciferase activity at increasing concentrations. Luciferase activity was reduced by 90% in cells transfected with 2'-F-GL2, but no significant reduction was seen in mocked transfected cells or with a control (2'-F-GFP=green fluorescent protein). The luciferase assay was carried out using a Luciferase assay system available from Promega Corp. (Madison, WI), according to the manufacturer's instructions.

The siRNA Chol-GL2 comprises a cholesteryl group on one of the 5' ends. 5-2 cells were incubated with various concentrations of Chol-GL2 in the absence of liposomes. Cells were harvested 48 hours after incubation and assayed for luciferase activity. Figure 12 shows that Chol-GL2 inhibited luciferase gene activity in a dose-dependent manner. InvA refers to chol-GL2 in inverted sequence.

EXAMPLE 10

To test the stability of 2' chemically modified siRNA compared to unmodified siRNA (siRNA), the following experiment is performed. Four nanograms of siRNA are added to a 20 μ L volume of 80% human serum from a healthy donor. This mixture is incubated at 37 C° for various times ranging from 1 minute up to 10 days. The results are depicted in lanes 2-10 of Figure 13. The same process is performed for 2' fluorine modified siRNA (2'-F siRNA) as well and the results are shown in lanes 12-20 and 22-25 of Figure 3. When the incubation process is finished, the mixtures are placed on ice and then immediately separated by PAGE along with a ³²P-siRNA control (See Lanes 1, 11 and 21 of Figure 13). The data show that the 2'-modified siRNA is stable over a period of 10 days as compared to unmodified siRNA.

EXAMPLE 11

To demonstrate the production of modified siRNA from long dsRNA, five micrograms of 1000 bp-long fluorinated dsRNAs (Figure 14, panel (A)) were incubated overnight with 15 units of human Dicer at 37°C. The resulting diced-

siRNAs were purified using a Sephadex™ G-25 column and electrophoresed on 20% PAGE (Figure 14, panel (B)). Figure 4 shows that recombinant human dicer effectively converts fluorinated-dsRNA into 2'F-siRNA.

EXAMPLE 12

To further test whether siRNAs directed to the HCV genome confer intracellular immunity against this human pathogen, the assay described in Example 1 was employed to test siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, and siRNA5B4, each of which is shown in Figure 2. Each siRNA was tested at concentrations of 1 nM, 10nM and 100 nM. As shown in Figure 15, each of the siRNAs significantly inhibited luciferase activity in a dose-dependent manner. SiRNAC2 exhibited particular effectiveness.

EXAMPLE 13

As a follow-up to the experiments reported in Example 9, assays were performed to demonstrate that the cholesterol modification, and not the fluoro modification directed siRNA molecules to Huh-7 liver cells. Huh-7 cells were incubated with various concentrations of two kinds of Chol-GL2 siRNAs: one having a 2'-fluoro modification and the other lacking such a modification. The results, shown in Figure 16 demonstrate that the deliver of cholesterol-modified siRNA molecules to liver cells is due to the cholesterol, and not other modifications.

SEQUENCE LISTING

<110> Novartis Vaccines and Diagnostics, Inc.

<120> MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE

<130> 5684-15

<140> CA 2,493,949

<141> 2003-07-25

<150> US 60/470,230

<151> 2003-05-14

<150> US 60/461,838

<151> 2003-04-11

<150> US 60/398,605

<151> 2002-07-26

<160> 67

<170> PatentIn Ver. 3.2

<210> 1

<211> 21

<212> RNA

<213> Hepatitis C virus

<400> 1

guacugccug auagggugcu u 21

<210> 2

<211> 21

<212> RNA

<213> Hepatitis C virus

<400> 2

gcacccuauu aggcaguacu u 21

<210> 3

<211> 21

<212> RNA

<213> Hepatitis C virus

<400> 3

cguacgcgga auacuucgau u 21

<210> 4

<211> 21

<212> RNA

<213> Hepatitis C virus

<400> 4

ucgaaguauu ccgcguacgu u 21

<210> 5
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 5
 cuuacgcuga guacuucgau u 21

<210> 6
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 6
 ucgaaguac ucagcguaagu u 21

<210> 7
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 7
 aucucuacgg ugguccuaau u 21

<210> 8
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 8
 uuaggaccac cguagagauu u 21

<210> 9
 <211> 383
 <212> RNA
 <213> Hepatitis C virus

<400> 9
 gccagcccc gauugggggc gacacuccac cauagauac uccccuguga ggaacuacug 60
 ucuucacgca gaaagcgucu agccauggcg uuaguaugag ugucgugcag ccuccaggac 120
 cccccuucc gggagagcca uaguggucug cggaaccggu gaguacaccg gaauugccag 180
 gacgaccggg uccuuucuug gaucaacccg cucaauggcu ggagauuugg gcgugcccc 240
 gcgagacugc uagccgagua guguuagguc gcgaaaggcc uugugguacu gccugauagg 300
 gugcuugcga gugccccggg agguucgua gaccgugcac caugagcacg aauccuaaac 360
 cucaaagaaa aaccaaacgu aac 383

<210> 10
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

<400> 10
 cccugugagg aacuacuguc uuc 23

<210> 11

<211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 11
 uacugucuuc acgcagaaag cgu 23

<210> 12
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 12
 cgagacugcu agccgaguag ugu 23

<210> 13
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 13
 gaauccuaaa ccucaaagaa aaa 23

<210> 14
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 14
 ggucagaucg ucgguggagu uua 23

<210> 15
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 15
 gguaagguca ucgauacccu cac 23

<210> 16
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 16
 acggcgugaa cuaugcaaca ggg 23

<210> 17
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 17
 ccgguugcuc cuuuucuauc uuc 23

<210> 18
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 18
 gcucuucaua cggauuccaa uac 23

 <210> 19
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 19
 cauacggauu ccaauacucu ccu 23

 <210> 20
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 20
 uuugacucua cggucacuga gaa 23

 <210> 21
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 21
 ccuucacgga ggcuaugacu aga 23

 <210> 22
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 22
 auacgacuug gaguugauaa cau 23

 <210> 23
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 23
 auuccuggcu aggcaacauc auc 23

 <210> 24
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

 <400> 24

uuguggcaag uaccucuca acu 23

<210> 25
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

<400> 25
 auguggugcc uacuccuacu uuc 23

<210> 26
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

<400> 26
 cuuugguggc uccaucuag ccc 23

<210> 27
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

<400> 27
 gucacggcua gcugugaaag guc 23

<210> 28
 <211> 23
 <212> RNA
 <213> Hepatitis C virus

<400> 28
 agccgcuuga cugcagagag ugc 23

<210> 29
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 29
 cugugaggaa cuacugucuu c 21

<210> 30
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 30
 agacaguagu uccucacagg g 21

<210> 31
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 31 cugucuucac gcagaaagcg u	21
<210> 32 <211> 21 <212> RNA <213> Hepatitis C virus	
<400> 32 gcuuucugcg ugaagacagu a	21
<210> 33 <211> 21 <212> RNA <213> Hepatitis C virus	
<400> 33 agacugcuag ccgaguagug u	21
<210> 34 <211> 21 <212> RNA <213> Hepatitis C virus	
<400> 34 acuacucggc uagcagucuc g	21
<210> 35 <211> 21 <212> RNA <213> Hepatitis C virus	
<400> 35 auccuaaacc ucaaagaaaa a	21
<210> 36 <211> 21 <212> RNA <213> Hepatitis C virus	
<400> 36 uuucuuugag guuuaggauu c	21
<210> 37 <211> 21 <212> RNA <213> Hepatitis C virus	
<400> 37 ucagaucguc gguggaguuu a	21
<210> 38 <211> 21	

<212> RNA
 <213> Hepatitis C virus

 <400> 38
 aacuccaccg acgaucugac c 21

 <210> 39
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

 <400> 39
 uaaggucauc gauaccuca c 21

 <210> 40
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

 <400> 40
 gagguaucg augaccuuac c 21

 <210> 41
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

 <400> 41
 ggcgugaacu augcaacagg g 21

 <210> 42
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

 <400> 42
 cuguugcaua guucacgccg u 21

 <210> 43
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

 <400> 43
 gguugcuccu uuucuaucuu c 21

 <210> 44
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

 <400> 44
 agauagaaaa ggagcaaccg g 21

<210> 45
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 45
 ucuucauacg gauuccaaua c

21

<210> 46
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 46
 auuggaaucc guaugaagag c

21

<210> 47
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 47
 uacggauucc aaucucucc u

21

<210> 48
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 48
 gagaguauug gaauccguau g

21

<210> 49
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 49
 ugacucaacg gucacugaga a

21

<210> 50
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 50
 cucagugacc guugagucaa a

21

<210> 51
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 51
 uucacggagg cuaugacuag a

21

<210> 52
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 52
 uagucauagc cuccgugaag g

21

<210> 53
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 53
 acgacuugga guugauaaca u

21

<210> 54
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 54
 guuaucaacu ccaagucgua u

21

<210> 55
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 55
 uccuggcuag gcaacaucau c

21

<210> 56
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 56
 ugauguugcc uagccaggaa u

21

<210> 57
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 57
 guggcaagua ccucuucaac u

21

<210> 58
 <211> 21
 <212> RNA
 <213> Hepatitis C virus

<400> 58	21
uugaagaggu acuugccaca a	
<210> 59	
<211> 21	
<212> RNA	
<213> Hepatitis C virus	
<400> 59	21
guggugccua cuccuacuuu c	
<210> 60	
<211> 21	
<212> RNA	
<213> Hepatitis C virus	
<400> 60	21
aaguaggagu aggcaccaca u	
<210> 61	
<211> 21	
<212> RNA	
<213> Hepatitis C virus	
<400> 61	21
uugguggcuc caucuagcc c	
<210> 62	
<211> 21	
<212> RNA	
<213> Hepatitis C virus	
<400> 62	21
gcuaagaugg agccaccaaa g	
<210> 63	
<211> 21	
<212> RNA	
<213> Hepatitis C virus	
<400> 63	21
cacggcuagc ugugaaaggu c	
<210> 64	
<211> 21	
<212> RNA	
<213> Hepatitis C virus	
<400> 64	21
ccuuucacag cuagccguga c	
<210> 65	
<211> 21	
<212> RNA	

<213> Hepatitis C virus

<400> 65

ccgcuugacu gcagagagug c

21

<210> 66

<211> 21

<212> RNA

<213> Hepatitis C virus

<400> 66

acucucugca gucaagcggc u

21

<210> 67

<211> 29751

<212> DNA

<213> Severe acute respiratory syndrome virus

<400> 67

```

ttattaggtt tttacctacc caggaaaagc caaccaacct cgatctcttg tagatctgtt 60
ctctaaacga actttaaaat ctgtgtagct gtcgctcggc tgcattgccta gtgcacctac 120
gcagtataaa caataataaa ttttactgtc gttgacaaga aacgagtaac tcgtccctct 180
tctgcagact gcttacgggt tcgtccgtgt tgcagtcgat catcagcata cctagggtttc 240
gtccgggtgt gaccgaaagg taagatggag agccttggtc ttggtgtcaa cgagaaaaca 300
cacgtccaac tcagtttgcc tgtccttcag gttagagacg tgctagtgcg tggcttcggg 360
gactctgttg aagaggccct atcggaggca cgtgaacacc tcaaaaatgg cacttgtggt 420
ctagtagagc tggaaaaagg cgtactgccc cagcttgaac agccctatgt gttcattaaa 480
cgttctgatg ccttaagcac caatcacggc cacaaggctc ttgagctggt tgcagaaatg 540
gacggcattc agtacggctc tagcgggtata acactgggag tactcgtgcc acatgtgggc 600
gaaaccccaa ttgcataacc caatgttctt cttcgtgaaga acggtaataa gggagccggt 660
ggtcatagct atggcatcga tctaaagtct tatgacttag gtgacgagct tggcactgat 720
cccattgaag attatgaaca aaactggaac actaagcatg gcagtgggtc actccgtgaa 780
ctcactcgtg agctcaatgg aggtgcagtc actcgtctatg tcgacaacaa tttctgtggc 840
ccagatgggt accctcttga ttgcatcaaa gattttctcg cacgcgcggg caagtcaatg 900
tgcactcttt ccgaacaact tgattacatc gagtcgaaga gaggtgtcta ctgctgccgt 960
gaccatgagc atgaaattgc ctggttcact gagcgtcttg ataagagcta cgagcaccag 1020
acacccttcg aaattaagag tgccaagaaa tttgacactt tcaaagggga atgcccaaag 1080
tttgtgtttc ctcttaactc aaaagtcaaa gtcattcaac cacgtgttga aaagaaaaag 1140
actgaggggt tcatggggcg tatacgctct gtgtaccctg ttgcatctcc acaggagtgt 1200
aacaatatgc acttgtctac cttgatgaaa tgtaatcatt gcgatgaagt ttcattggcag 1260
acgtgcgact ttctgaaagc cacttgtgaa cattgtggca ctgaaaattt agttattgaa 1320
ggacctacta catgtgggta cctacctact aatgctgtag tgaaaatgcc atgtcctgcc 1380
tgtcaagacc cagagattgg acctgagcat agtggtgcag attatcacia ccactcaaac 1440
attgaaactc gactccgcaa gggaggtagg actagatgtt ttggaggctg tgtgtttgcc 1500
tatgttggct gctataataa gcgtgcctac tgggttcctc gtgctagtgc tgatattggc 1560
tcaggccata ctggcattac tggtgacaat gtggagacct tgaatgagga tctccttgag 1620
atactgagtc gtgaacgtgt taacattaac attgttggcg attttcattt gaatgaagag 1680
gttgccatca ttttggcatc tttctctgct tctacaagtg cctttattga cactataaag 1740
agtcttgatt acaagtcttt caaaaccatt gttgagtcct gcggtaacta taaagttacc 1800
aagggaaagc ccgtaaaagg tgcttggaac attggacaac agagatcagt tttaacacca 1860
ctgtgtgggt ttccctcaca ggctgctggt gttatcagat caatttttgc gcgcacactt 1920
gatgcagcaa accactcaat tcctgatttg caaagagcag ctgtcaccat acttgatggt 1980
atcttctgaa agtcattacg tcttgctgac gccatgggtt atacttcaga cctgctcacc 2040
aacagtgtca ttattatggc atatgtaact ggtggctctg tacaacagac ttctcagtgg 2100
ttgtctaate ttttgggcac tactgttgaa aaactcaggc ctatctttga atggattgag 2160
gcgaaactta gtgcaggagt tgaatttctc aaggatgctt gggagattct caaatttctc 2220
attacaggtg tttttgacat cgtcaagggt caaatacagg ttgcttcaga taacatcaag 2280
gattgtgtaa aatgcttcat tgatgttggt aacaaggcac tcgaaatgtg cattgatcaa 2340
gtcactatcg ctggcgcaaa gttgcgatca ctcaacttag gtgaagtctt catcgtcaa 2400

```

agcaagggac	tttaccgtca	gtgtatacgt	ggcaaggagc	agctgcaact	actcatgcct	2460
cttaaggcac	caaaagaagt	aacctttctt	gaagggtgatt	cacatgacac	agtacttacc	2520
tctgaggagg	ttgttctcaa	gaacgggtgaa	ctcgaagcac	tcgagacgcc	cgttgatagc	2580
ttcacaaatg	gagctatcgt	cggcacacca	gtctgtgtaa	atggcctcat	gctcttagag	2640
attaaggaca	aagaacaata	ctgcgcattg	tctcctgggt	tactggctac	aaacaatgtc	2700
tttcgcttaa	aaggggggtgc	accaattaaa	ggtgtaacct	ttggagaaga	tactgttttg	2760
gaagttcaag	gttacaagaa	tgtgagaatc	acatttgagc	ttgatgaacg	tgttgacaaa	2820
gtgcttaatg	aaaagtgtc	tgtctacact	gttgaatccg	gtaccgaagt	tactgagttt	2880
gcatgtgttg	tagcagaggc	tgttgatgaag	acttttacaac	cagtttctga	tctccttacc	2940
aacatgggta	ttgatcttga	tgagtggagt	gtagctacat	tctacttatt	tgatgatgct	3000
ggtgaagaaa	acttttcatc	acgtatgtat	tgttcctttt	accctccaga	tgaggaagaa	3060
gaggacgatg	cagagtgtga	ggaagaagaa	attgatgaaa	cctgtgaaca	tgagtacggg	3120
acagaggatg	attatcaagg	tctccctctg	gaatttggtg	cctcagctga	aacagttcga	3180
gttgaggaag	aagaagagga	agactggctg	gatgatacta	ctgagcaatc	agagattgag	3240
ccagaaccag	aacctacacc	tgaagaacca	gttaatcagt	ttactgggta	tttaaaactt	3300
actgacaatg	ttgccattaa	atgtgttgac	atcgtttaagg	aggcacaaag	tgctaatect	3360
atggtgattg	taaatgctgc	taacatacac	ctgaaacatg	gtgggtgggtg	agcagggtgca	3420
ctcaacaagg	caaccaatgg	tgccatgcaa	aaggagagtg	atgattacat	taagctaaat	3480
ggccctctta	cagtaggagg	gtcttggttg	ctttctggac	ataatcttgc	taagaagtgt	3540
ctgcatgttg	ttggacctaa	cctaaatgca	ggtgaggaca	tccagcttct	taaggcagca	3600
tatgaaaatt	tcaattcaca	ggacatctta	cttgccaccat	tggtgtcagc	aggcatattt	3660
ggtgctaaac	cacttcagtc	tttacaagtg	tgcggtgcaga	cggttcgtac	acaggtttat	3720
attgcagtc	atgacaaagc	tcttttatgag	caggttggtca	tggattatct	tgataacctg	3780
aagcctagag	tggaagcacc	taaacaagag	gagccacca	acacagaaga	ttccaaaact	3840
gaggagaaat	ctgtcgtaca	gaagcctgtc	gatgtgaagc	caaaaattaa	ggcctgcatt	3900
gatgagggtta	ccacaacact	ggaagaaact	aagtttctta	ccaataagtt	actcttggtt	3960
gctgatataca	atggtaagct	ttaccatgat	tctcagaaca	tgcttagagg	tgaagatatg	4020
tctttccttg	agaaggatgc	accttacatg	gtagggtgatg	ttatcactag	tggtgatatac	4080
acttggtgttg	taataccctc	caaaaaggct	ggtggcacta	ctgagatgct	ctcaagagct	4140
ttgaagaaag	tgccagttga	tgagtatata	accacgtacc	ctggacaagg	atgtgctggg	4200
tatacacttg	aggaagctaa	gactgctctt	aagaaatgca	aatctgcatt	ttatgtacta	4260
ccttcagaag	cacctaatgc	taaggaagag	attctaggaa	ctgtatcctg	gaatttgaga	4320
gaaatgcttg	ctcatgctga	agagacaaga	aaattaatgc	ctatatgcat	ggatgttaga	4380
gccataatgg	caaccatcca	acgtaagtat	aaaggaatta	aaattcaaga	gggcatcggt	4440
gactatgggtg	tccgattctt	ctttttatact	agtaaagagc	ctgtagcttc	tattattacg	4500
aagctgaact	ctctaaatga	gccgcttggtc	acaatgccaa	ttgggttatgt	gacacatggg	4560
tttaatcttg	aagaggctgc	gcgctgtatg	cgttctctta	aagctcctgc	cgtagtgtca	4620
gtatcatcac	cagatgctgt	tactacatat	aatggatacc	tcacttcgtc	atcaaagaca	4680
tctgaggagc	actttgtaga	aacagtttct	ttggctgggt	cttacagaga	ttggctctat	4740
tcaggacagc	gtacagagtt	aggtgttgaa	tttcttaagc	gtgggtgacaa	aattgtgtac	4800
cacactctgg	agagccccgt	cgagtttcat	cttgacgggtg	aggttctttc	acttgacaaa	4860
ctaaagagtc	tcttatccct	gcgggagggt	aagactataa	aagtgttcac	aactgtggac	4920
aacactaatc	tccacacaca	gcttggtgat	atgtctatga	catatggaca	gcagtttggt	4980
ccaacatact	tggtatgggtg	tgatgttaca	aaaattaaac	ctcatgtaaa	tcatgagggt	5040
aagactttct	ttgtactacc	tagtgatgac	acactacgta	gtgaagcttt	cgagtactac	5100
catactcttg	atgagagttt	tcttggtagg	tacatgtctg	ctttaaacca	cacaaagaaa	5160
tggaattttc	ctcaagttgg	tggttttaact	tcaattaaat	gggctgataa	caattgttat	5220
ttgtctagtg	ttttatttagc	acttcaacag	cttgaagtca	aattcaatgc	accagcactt	5280
caagaggctt	attatagagc	ccgtgctggg	gatgctgcta	acttttgtgc	actcatactc	5340
gcttacagta	ataaaaactgt	tggcgagctt	ggtgatgtca	gagaaactat	gacctatctt	5400
ctacagcatg	ctaatttgga	atctgcaaag	cgagttctta	atgtgggtgtg	taaacattgt	5460
ggtcagaaaa	ctactacctt	aacgggtgta	gaagctgtga	tgtatatggg	tactctatct	5520
tatgataatc	ttaagacagg	tgtttccatt	ccatgtgtgt	gtgggtcgtga	tgctacacaa	5580
tatctagtag	aacaagagtc	ttcttttgtt	atgatgtctg	caccacctgc	tgagtataaa	5640
ttacagcaag	gtacattctt	atgtgcgaat	gagtacactg	gtaactatca	gtgtgggtcat	5700
tacactcata	taactgctaa	ggagaccctc	tatcgtattg	acggagctca	ccttacaaag	5760
atgtcagagt	acaaaggacc	agtgactgat	gttttctaca	aggaaacatc	ttacactaca	5820
accatcaagc	ctgtgtcgtg	taaaactcgat	ggagttactt	acacagagat	tgaacccaaa	5880
ttggatgggt	attataaaaa	ggataatgct	tactatacag	agcagcctat	agaccttgta	5940
ccaactcaac	cattaccaaa	tgcgagtttt	gataatttca	aactcacatg	ttctaacaca	6000
aaatttgctg	atgatttaaa	tcaaatgaca	ggcttcacaa	agccagcttc	acgagagcta	6060

tctgtcacat	tcttcccaga	cttgaatggc	gatgtagtgg	ctattgacta	tagacactat	6120
tcagcgagtt	tcaagaaagg	tgctaaatta	ctgcataagc	caattgtttg	gcacattaac	6180
caggctacaa	ccaagacaac	gttcaaacca	aacacttggg	gtttacggtg	tctttggagt	6240
acaaagccag	tagatacttc	aaattcattt	gaagttctgg	cagtagaaga	cacacaagga	6300
atggacaatc	ttgcttgtga	aagtcaacaa	cccacctctg	aagaagtagt	ggaaaatcct	6360
accatacaga	aggaagtcac	agagtgtgac	gtgaaaacta	ccgaagttgt	aggcaatgtc	6420
atacttaaac	catcagatga	aggtgttaaa	gtaacacaag	agttagggtca	tgaggatctt	6480
atggctgctt	atgtggaaaa	cacaagcatt	accattaaga	aacctaatga	gctttcacta	6540
gccttagggt	taaaaacaat	tgccactcat	ggtattgctg	caattaatag	tgttccttgg	6600
agtaaaattt	tggttatgt	caaaccattc	ttaggacaag	cagcaattac	aacatcaaat	6660
tgcgctaaga	gattagcaca	acgtgtgttt	aacaattata	tgcttatgt	gtttacatta	6720
ttgttccaat	tgtgtacttt	tactaaaagt	accaattcta	gaattagagc	ttcactacct	6780
acaactattg	ctaaaaatag	tgtaagagt	gttgctaaat	tatgtttgga	tgccggcatt	6840
aattatgtga	agtcacccaa	attttctaaa	ttgttcacaa	tcgctatgtg	gctattgttg	6900
ttaagtattt	gcttaggttc	tctaactctgt	gtaactgctg	cttttggtgt	actcttatct	6960
aattttggtg	ctccttctta	ttgtaatggc	gtagagaat	tgtatcttaa	ttcgtctaac	7020
gttactacta	tggtttctg	tgaaggttct	tttccttgca	gcatttggtt	aagtggatta	7080
gactcccttg	attcttatcc	agctcttgaa	accattcagg	tgacgatttc	atcgtacaag	7140
ctagacttga	caatttttagg	tctggccgct	gagtgggttt	tgccatata	gttgttcaca	7200
aaattctttt	atttattagg	tctttcagct	ataatgcagg	tggtcttttg	ctattttgct	7260
agtcatttca	tcagcaattc	ttggctcatg	tggtttatca	ttagtattgt	acaaatggca	7320
cccgtttctg	caatggttag	gatgtacatc	ttctttgctt	ctttctacta	catatggaag	7380
agctatgttc	atatcatgga	tggttgccac	tcttcgactt	gcctgatgtg	ctataagcgc	7440
aatcgtgcca	cacgcgttga	gtgtacaact	attgttaatg	gcctgaagag	atctttctat	7500
gtctatgcaa	atggaggccg	tggttcttgc	aagactcaca	attggaattg	tctcaattgt	7560
gacacatttt	gcactggtag	tacattcatt	agtgatgaag	ttgctcgtga	tttgtcactc	7620
cagtttaaaa	gaccaatcaa	ccctactgac	cagtcctcgt	atattgttga	tagtgttgct	7680
gtgaaaaatg	gcgcgcttca	cctctacttt	gacaaggctg	gtcaaaaagac	ctatgagaga	7740
catccgctct	cccattttgt	caatttagac	aatttgagag	ctaacaacac	taaaggttca	7800
ctgcctatta	atgtcatagt	ttttgatggc	aagtccaaat	gcgacgagtc	tgcttctaag	7860
tctgcttctg	tgtactacag	tcagctgatg	tgccaacctc	ttctgttgct	tgaccaagct	7920
cttgatcatg	acgttggaga	tagtactgaa	gtttccgtta	agatgtttga	tgcttatgtc	7980
gacacctttt	cagcaacttt	tagtgttcct	atggaaaaac	ttaaggcact	tggtgttaca	8040
gctcacagcg	agttagcaaa	gggtgtagct	ttagatgggt	tcctttctac	attcgtgtca	8100
gctgcccgcg	aagggtgttg	tgataccgat	gttgacacaa	aggatgttat	tgaatgtctc	8160
aaactttcac	atcactctga	cttagaagtg	acagggtgaca	gttgtaacaa	tttcatgctc	8220
acctataata	aggttgaaaa	catgacgccc	agagatcttg	gcgcatgtat	tgactgtaat	8280
gcaaggcata	tcaatgcccc	agtagcaaaa	agtcacaatg	tttcaactcat	ctggaatgta	8340
aaagactaca	tgtctttatc	tgaacagctg	cgtaaacaaa	ttcgtagtgc	tgccaagaag	8400
aacaacatac	cttttagact	aacttgtgct	acaactagac	aggttgtcaa	tgtcataact	8460
actaaaatct	cactcaaggg	tggttaagatt	gttagtactt	gttttaaaact	tatgcttaag	8520
gccacattat	tgtgcgttct	tgctgcattg	gtttgttata	tcgttatgcc	agtacataca	8580
ttgtcaatcc	atgatggtta	cacaaatgaa	atcattgggt	acaaagccat	tcaggatggg	8640
gtcactcgtg	acatcatttc	tactgatgat	tgttttgcaa	ataaacatgc	tggttttgac	8700
gcctggttta	gccagcgtgg	tggttcatac	aaaaatgaca	aaagctgccc	tgtagtagct	8760
gctatcatta	caagagagat	tggtttcata	gtgcctggct	taccgggtac	tgtgctgaga	8820
gcaatcaatg	gtgacttctt	gcattttcta	cctcgtgttt	ttagtgctgt	tggaacatt	8880
tgctacacac	cttccaaact	cattgagtat	agtgattttg	ctacctctgc	ttgcgttctt	8940
gctgctgagt	gtacaatttt	taaggatgct	atgggcaaac	ctgtgccata	ttgttatgac	9000
actaatttgc	tagagggttc	tatttcttat	agtgaagctc	gtccagacac	tcgttatgtg	9060
cttatggatg	gttccatcat	acagtttctt	aacacttacc	tggaagggtc	tgttagagta	9120
gtaacaactt	ttgatgctga	gtactgtaga	catggtacat	gcgaaagggtc	agaagtaggt	9180
atgttgctat	ctaccagtg	tagatgggtt	cttaataatg	agcattacag	agctctatca	9240
ggagttttct	gtgggtgttg	tgcatgaat	ctcatagcta	acatctttac	tcctcttgtg	9300
caacctgtgg	gtgctttaga	tgtgtctgct	tcagtagtgg	ctgggtgtat	tattgccata	9360
ttggtgactt	gtgctgccta	ctactttatg	aaattcagac	gtgttttttg	tgagtacaac	9420
catgttggtg	ctgctaattgc	acttttggtt	ttgatgtctt	tcactatact	ctgtctggta	9480
ccagcttaca	gctttctgcc	gggagctctac	tcagtctttt	acttgtactt	gacattctat	9540
ttcaccaatg	atgtttcatt	cttggtctac	cttcaatggt	ttgccatgtt	ttctcctatt	9600
gtgccttttt	ggataacagc	aatctatgta	ttctgtattt	ctctgaagca	ctgccattgg	9660
ttctttaaca	actatcttag	gaaaagagtc	atgtttaatg	gagttacatt	tagtaccttc	9720

gaggaggctg	ctttgtgtac	cttttttgc	aacaaggaaa	tgtacctaaa	attgcgtagc	9780
gagacactgt	tgccacttac	acagtataac	aggatatctg	ctctatataa	caagtacaag	9840
tatttcagtg	gagccttaga	tactaccagc	tatcgtgaag	cagcttgctg	ccacttagca	9900
aaggctctaa	atgacttttag	caactcaggt	gctgatgttc	tctaccaacc	accacagaca	9960
tcaatcactt	ctgctgttct	gcagagtgg	tttaggaaaa	tggcattccc	gtcaggcaaa	10020
gttgaagggt	gcatgggtaca	agtaacctgt	ggaactacaa	ctcttaaatg	attgtggttg	10080
gatgacacag	tatactgtcc	aagacatgtc	atgtgcacag	cagaagacat	gcttaatcct	10140
aactatgaag	atctgctcat	tgcgaaatcc	aaccatagct	ttcttggtca	ggctggcaat	10200
gttcaacttc	gtgttatttg	ccattctatg	caaaattgtc	tgttaggct	taaagttagt	10260
acttctaacc	ctaagacacc	caagtataaa	tttgtccgta	tccaacctgg	tcaaacattt	10320
tcagttctag	catgctacaa	tggttcacca	tctggtgttt	atcagtgtgc	catgagacct	10380
aatcatacca	ttaaagggtc	tttccctaat	ggatcatgtg	gtagtgttg	ttttaacatt	10440
gattatgatt	gcgtgtcttt	ctgctatatg	catcatatgg	agcttccaac	aggagtacac	10500
gctgggtactg	acttagaagg	taaattctat	ggctccatttg	ttgacagaca	aactgcacag	10560
gctgcaggta	cagacacaa	cataacatta	aatgttttgg	catggctgta	tgtgtgtgtt	10620
atcaatggtg	atagggtggt	tcttaataga	ttcaccacta	ctttgaatga	ctttaacctt	10680
gtggcaatga	agtacaacta	tgaacctttg	acacaagatc	atgttgacat	attgggacct	10740
ctttctgctc	aaacaggaat	tgcggtctta	gatagtgtgt	ctgctttgaa	agagctgctg	10800
cagaatggta	tgaatggtcg	tactatcctt	ggtagcacta	ttttagaaga	tgagtttaca	10860
ccatttgatg	ttgttagaca	atgctctggt	gttaccttcc	aaggtaagtt	caagaaaatt	10920
gttaagggca	ctcatcattg	gatgctttta	actttcttga	catcactatt	gattcttggt	10980
caaagtacac	agtgggtcact	gtttttcttt	gtttacgaga	atgctttctt	gccatttact	11040
cttgggtatta	tggcaattgc	tgcagtgtgt	atgctgcttg	ttaagcataa	gcacgcattc	11100
ttgtgcttgt	ttctgttacc	ttctcttgca	acagttgctt	actttaatat	ggtctacatg	11160
cctgctagct	gggtgatgcg	tatcatgaca	tggcttgaat	tggctgacac	tagcttgtct	11220
ggttataggg	ttaaggattg	tgttatgtat	gcttcagctt	tagttttgct	tattctcatg	11280
acagctcgca	ctgtttatga	tgatgctgct	agacgtgttt	ggacactgat	gaatgtcatt	11340
acacttggtt	acaaagtcta	ctatggtaat	gcttttagatc	aagctatttc	catgtggggc	11400
ttagttattt	ctgtaacctc	taactattct	ggtgtcgtta	cgactatcat	gttttttagct	11460
agagctatag	tgtttgtgtg	tgttgagtat	taccattgt	tatttattac	tggcaacacc	11520
ttacagtgtg	tcatgcttgt	ttattgtttc	ttaggctatt	gttgctgctg	ctactttggc	11580
cttttctggt	tactcaaccg	ttacttcagg	cttactcttg	gtgtttatga	ctacttggtc	11640
tctacacaag	aatttaggta	tatgaactcc	caggggcttt	tgcctcctaa	gagtagtatt	11700
gatgctttca	agcttaacat	taagttgttg	ggtattggag	gtaaaccatg	tatcaagggt	11760
gctactgtac	agtctaaaa	gtctgacgta	aagtgcacat	ctgtgggtact	gctctcggtt	11820
cttcaacaac	ttagagttaga	gtcatcttct	aaattgtggg	cacaatgtgt	acaactccac	11880
aatgatattc	ttcttgcaaa	agacacaact	gaagctttcg	agaagatgg	ttctcttttg	11940
tctgttttgc	tatccatgca	gggtgctgta	gacattaata	ggttgtgcga	ggaaatgctc	12000
gataaccgtg	ctactcttca	ggctattgct	tcagaattta	gttctttacc	atcatatgcc	12060
gcttatgcc	ctgcccagga	ggcctatgag	caggctgtag	ctaattggtga	ttctgaagtc	12120
gttctcaaaa	agttaaagaa	atctttgaat	gtggctaaat	ctgagtttga	ccgtgatgct	12180
gccatgcaac	gcaagttgga	aaagatggca	gatcaggcta	tgacccaaat	gtacaaacag	12240
gcaagatctg	aggacaagag	ggcaaaagta	actagtgtca	tgcaaacat	gctcttcaact	12300
atgcttagga	agcttgataa	tgatgcactt	aacaacatta	tcaacaatgc	gcgtgatgg	12360
tgtgttccac	tcaacatcat	accattgact	acagcagcca	aactcatggt	tgttgctcct	12420
gattatggta	cctacaagaa	cacttgatgt	ggtaaacact	ttacatatgc	atctgcactc	12480
tgggaaatcc	agcaagttgt	tgatgcggat	agcaagattg	ttcaacttag	tgaatttaac	12540
atggacaatt	caccaaattt	ggcttggcct	cttattgtta	cagctctaag	agccaactca	12600
gctgttaa	tacagaataa	tgaactgagt	ccagtagcac	tacgacagat	gtcctgtgcg	12660
gctggtacca	cacaaacagc	ttgtactgat	gacaatgcac	ttgcctacta	taacaattcg	12720
aaggagggt	ggtttgtgct	ggcattacta	tcagaccacc	aagatctcaa	atgggctaga	12780
ttccctaaga	gtgatgggtac	aggtacaatt	tacacagaac	tggaaaccacc	ttgtagggtt	12840
gttacagaca	caccaaagg	gcctaaagt	aaatacttgt	acttcatcaa	aggcttaaac	12900
aacctaaata	gaggtatggt	gctgggcagt	ttagctgtca	cagtacgtct	tcaggctgga	12960
aatgctacag	aagtacctgc	caattcaact	gtgctttcct	tctgtgcttt	tgcagtagac	13020
cctgctaaag	catataagga	ttacctagca	agtggaggac	aaccaatcac	caactgtgtg	13080
aagatgttgt	gtacacacac	tggtagagga	caggcaatta	ctgtaacacc	agaagctaac	13140
atggaccaag	agtccttttg	tgggtgcttca	tgttgtctgt	attgtagatg	ccacattgac	13200
catocaaatc	ctaaaggatt	ctgtgacttg	aaaggtaagt	acgtccaaat	acctaccact	13260
tgtgctaagt	acccagtggg	ttttacactt	agaaacacag	tctgtaccgt	ctgcggaatg	13320
tggaaagggt	atggctgtag	ttgtgaccaa	ctccgcgaac	ccttgatgca	gtctgcggat	13380

gcatcaacgt	ttttaaacgg	gtttgcggtg	taagtgcagc	ccgtctttaca	ccgtgcggca	13440
caggcactag	tactgatgtc	gtctacaggg	cttttgatat	ttacaacgaa	aaagttgctg	13500
gttttgcaaa	gttcctaaaa	actaattgct	gtcgcttcca	ggagaaggat	gaggaaggca	13560
atttattaga	ctcttacttt	gtagttaaga	ggcatactat	gtctaactac	caacatgaag	13620
agactattta	taacttggtt	aaagattgtc	cagcggttgc	tgtccatgac	tttttcaagt	13680
ttagagtaga	tggtgacatg	gtaccacata	tatcacgtca	gcgtctaact	aaatacacaa	13740
tggctgattt	agtctatgct	ctacgtcatt	ttgatgaggg	taattgtgat	acattaaaag	13800
aaatactcgt	cacatacaat	tgctgtgatg	atgattattt	caataagaag	gattggtatg	13860
acttcgtaga	gaatcctgac	atcttacgcg	tatatgctaa	cttaggtgag	cgtgtacgcc	13920
aatcattatt	aaagactgta	caattctgcg	atgctatgcg	tgatgcaggc	attgtaggcg	13980
tactgacatt	agataatcag	gatcttaatg	ggaactggta	cgatttcggt	gatttcgtac	14040
aagtagcacc	aggctgcgga	gttcctattg	tggattcata	ttactcattg	ctgatgcccc	14100
tcctcacttt	gactagggca	ttggctgctg	agtcccatat	ggatgctgat	ctcgcaaaac	14160
cacttattaa	gtgggatttg	ctgaaatatg	atttttacgga	agagagactt	tgtctcttcg	14220
accgttattt	taaatattgg	gaccagacat	accatcccaa	ttgtattaac	tgtttggatg	14280
ataggtgtat	ccttcattgt	gcaaacttta	atgtgttatt	ttctactgtg	tttccacctt	14340
caagttttgg	accactagta	agaaaaatat	ttgtagatgg	tgttcctttt	gttgtttcaa	14400
ctggatacca	ttttcgtgag	ttaggagtcg	tacataatca	ggatgtaaac	ttacatagct	14460
cgcgtctcag	tttcaaggaa	cttttagtgt	atgctgctga	tccagctatg	catgcagctt	14520
ctggcaattt	attgctagat	aaacgcacta	catgcttttc	agtagctgca	ctaacaacaa	14580
atgttgcttt	tcaaactgtc	aaaccgggta	attttaataa	agacttttat	gactttgctg	14640
tgtctaaagg	tttctttaag	gaaggaagtt	ctggtgaact	aaaacacttc	ttctttgctc	14700
aggatggcaa	cgctgctatc	agtgattatg	actattatcg	ttataatctg	ccaacaatgt	14760
gtgatatcag	acaactccta	ttcgtagttg	aagttgttga	taaatacttt	gattgttacg	14820
atggtggctg	tattaatgcc	aaccaagtaa	tcgttaacaa	tctggataaa	tcagctgggt	14880
tcccatttaa	taaatggggg	aaggctagac	tttattatga	ctcaatgagt	tatgaggatc	14940
aagatgcact	tttcgcgtat	actaagcgta	atgtcatccc	tactataact	caaatagaatc	15000
ttaagtatgc	cattagtgc	aagaatagag	ctcgcaccgt	agctgggtgc	tctatctgta	15060
gtactatgac	aaatagacag	tttcatcaga	aattattgaa	gtcaatagcc	gccactagag	15120
gagctactgt	ggtaattgga	acaagcaagt	tttacgggtg	ctggcataat	atgttaaaaa	15180
ctgtttacag	tgatgtagaa	actccacacc	ttatgggttg	ggattatcca	aaatgtgaca	15240
gagccatgcc	taacatgctt	aggataatgg	cctctcttgt	tcttgctcgc	aaacataaca	15300
cttgctgtaa	cttatcacac	cgtttctaca	ggttagctaa	cgagtgtgcg	caagtattaa	15360
gtgagatgg	catgtgtggc	ggctcactat	atgttaaacc	aggtggaaca	tcataccggtg	15420
atgctacaac	tgcttatgct	aatagtgtct	ttaacatttg	tcaagctgtt	acagccaatg	15480
taaatgcact	tctttcaact	gatggtaata	agatagctga	caagtatgtc	cgcaatctac	15540
aacacaggct	ctatgagtgt	ctctatagaa	atagggatgt	tgatcatgaa	ttcgtggatg	15600
agttttacgc	ttacctgcgt	aaacatttct	ccatgatgat	tctttctgat	gatgccgttg	15660
tgtgctataa	cagtaactat	gcggctcaag	gtttagtagc	tagcatttaag	aactttaagg	15720
cagttcttta	ttatcaaaa	aatgtgttca	tgtctgaggc	aaaatgttgg	actgagactg	15780
accttactaa	aggacctcac	gaattttgct	cacagcatac	aatgctagtt	aaacaaggag	15840
atgattacgt	gtacctgcct	taccagatc	catcaagaat	attaggcgca	ggctgttttg	15900
tcgatgatat	tgtcaaaaca	gatggtacac	ttatgattga	aaggttcgtg	tcactggcta	15960
ttgatgctta	cccacttaca	aaacatccta	atcaggagta	tgctgatgtc	tttcaactgt	16020
atttacaata	cattagaaag	ttacatgatg	agcttactgg	ccacatgttg	gacatgtatt	16080
ccgtaatgct	aactaatgat	aacacctcac	ggtactggga	acctgagttt	tatgaggcta	16140
tgtacacacc	acatacagtc	ttgcaggctg	taggtgcttg	tgtattgtgc	aattcacaga	16200
cttcacttcg	ttgcggtgcc	tgtattagga	gaccattcct	atgttgcaag	tgctgctatg	16260
accatgtcat	ttcaacatca	cacaaattag	tgttgctctg	taatccctat	gttttgcaatg	16320
ccccagggtg	tgatgtcact	gatgtgacac	aactgtatct	aggaggtatg	agctattatt	16380
gcaagtcaca	taagcctccc	attagttttc	cattatgtgc	taatggtcag	gttttttggtt	16440
tatacaaaaa	cacatgtgta	ggcagtgaca	atgtcactga	cttcaatgcg	atagcaacat	16500
gtgattggac	taatgctggc	gattacatac	ttgccaacac	ttgtactgag	agactcaagc	16560
ttttcgcagc	agaaacgctc	aaagccactg	aggaaacatt	taagctgtca	tatgggtattg	16620
coactgtacg	cgaagtactc	tctgacagag	aattgcactc	ttcatgggag	gttggaacac	16680
ctagaccacc	attgaacaga	aactatgtct	ttactggtta	ccgtgtaact	aaaaatagta	16740
aagtacagat	tggagagtac	acctttgaaa	aaggtgacta	tggtgatgct	gttggtgtaca	16800
gaggtactac	gacatacaag	ttgaatgttg	gtgattactt	tgtgttgaca	tctcacactg	16860
taatgccact	tagtgcacct	actctagtgc	cacaagagca	ctatgtgaga	attactggct	16920
tgtacccaac	actcaacatc	tcagatgagt	tttctagcaa	tgttgcaaat	tatcaaaagg	16980
tcggcatgca	aaagtactct	acactccaag	gaccacctgg	tactggtaag	agtcattttg	17040

ccatcggact	tgctctctat	tacccatctg	ctcgcatagt	gtatacggca	tgctctcatg	17100
cagctggtga	tgccctatgt	gaaaaggcat	taaaatattt	gcccatagat	aaatgtagta	17160
gaatcatacc	tgcgcgtgcg	cgcgtagagt	gttttgataa	attcaaagtg	aattcaacac	17220
tagaacagta	tgttttctgc	actgtaaatg	cattgocaga	aacaactgct	gacattgtag	17280
tctttgatga	aatctctatg	gctactaatt	atgacttgag	tgttgtcaat	gctagacttc	17340
gtgcaaaaca	ctacgtctat	attggcgatc	ctgctcaatt	accagccccc	cgcacattgc	17400
tgactaaagg	cacactagaa	ccagaatatt	ttaattcagt	gtgcagactt	atgaaaacaa	17460
taggtccaga	catgttcctt	ggaacttgct	gccgttgctc	tgctgaaatt	gttgacactg	17520
tgagtgcctt	agtttatgac	aataagctaa	aagcacacaa	ggataagtca	gctcaatgct	17580
tcaaaatggt	ctacaaagg	gttattacac	atgatgtttc	atctgcaatc	aacagacctc	17640
aataggcgt	tgtaagagaa	tttcttacac	gcaatcctgc	ttggagaaaa	gctgttttta	17700
tctcacctta	taattcacag	aacgctgtag	cttcaaaaat	cttaggattg	cctacgcaga	17760
ctgttgattc	atcacagggt	tctgaatatg	actatgtcat	attcacacaa	actactgaaa	17820
cagcacactc	ttgtaatgct	aaccgcttca	atgtggctat	cacaagggca	aaaattggca	17880
ttttgtgcat	aatgtctgat	agagatcttt	atgacaaact	gcaatttaca	agtctagaaa	17940
taccacgtcg	caatgtggct	acattacaag	cagaaaatgt	aactggactt	tttaaggact	18000
gtagtaagat	cattactgg	cttcatccta	cacaggcacc	tacacacctc	agcgttgata	18060
taaagttcaa	gactgaagga	ttatgtgttg	acataccagg	cataccaaag	gacatgacct	18120
accgtagact	catctctatg	atgggtttca	aatgaatta	ccaagtcaat	ggttacccta	18180
atatgtttat	caccgcgaa	gaagctattc	gtcacgttcg	tgcgtggatt	ggctttgatg	18240
tagagggctg	tcatgcaact	agagatgctg	tgggtactaa	cctacctctc	cagctaggat	18300
tttctacagg	tgtaaactta	gtagctgtac	cgactggtta	tggtgacact	gaaaataaca	18360
cagaattcac	cagagttaat	gcaaaacctc	caccagggtga	ccagttttaa	catcttatac	18420
cactcatgta	taaaggcttg	ccctggaatg	tagtgcgat	taagatagta	caaagtctca	18480
gtgatacact	gaaaggattg	tcagacagag	tcgtgttcgt	cctttgggcg	catggctttg	18540
agcttacatc	aatgaagtac	tttgtcaaga	ttggacctga	aagaacgtgt	tgtctgtgtg	18600
acaaacgtgc	aacttgcttt	tctacttcat	cagatactta	tgcctgctgg	aatcattctg	18660
tgggttttga	ctatgtctat	aaccoattta	tgattgatgt	tcagcagtgg	ggctttacgg	18720
gtaaccttca	gagtaacct	gaccaacatt	gccagggtaca	tggaaatgca	catgtggcta	18780
gttgtgatgc	tatcatgact	agatgtttag	cagtccatga	gtgctttgtt	aagcgcgttg	18840
attggctctgt	tgaataccct	attataggag	atgaactgag	ggttaattct	gcttgacaga	18900
aagtacaaca	catgggtgtg	aagtctgcat	tgcttgctga	taagtttcca	gttcttcatg	18960
acattggaaa	tccaaaggct	atcaagtgtg	tgcctcaggc	tgaagtagaa	tggaaagtct	19020
acgatgctca	gccatgtagt	gacaaagctt	acaaaataga	ggaactcttc	tattcttatg	19080
ctacacatca	cgataaatto	actgatgggt	tttgtttggt	ttggaattgt	aacgttgatc	19140
gttaccacgc	caatgcaatt	gtgtgtaggt	ttgacacaag	agtcttgctca	aacttgaact	19200
taccaggctg	tgatgggtgg	agtttgtagt	tgaataagca	tgcatccac	actccagctt	19260
tcgataaaaag	tgcatcttact	aatttaaagc	aattgccttt	cttttactat	tctgatagtc	19320
cttgtgagtc	tcatggcaaa	caagtagtgt	cggatattga	ttatgttcca	ctcaaactctg	19380
ctacgtgtat	tacacgatgc	aatttaggtg	gtgctgtttg	cagacaccat	gcaaatgagt	19440
accgacagta	cttggatgca	tataatatga	tgatttctgc	tggatttagc	ctatggattt	19500
acaaacaatt	tgatacttat	aacctgtgga	atacattttac	caggttacag	agtttagaaa	19560
atgtggctta	taatgttggt	aataaaggac	actttgatgg	acacgccggc	gaagcacctg	19620
tttccatcat	taataatgct	gtttacacaa	aggtagatgg	tattgatgtg	gagatctttg	19680
aaaataagac	aacacttcct	gttaatgttg	catttgagct	ttgggctaag	cgtaacatta	19740
aaccagtgcc	agagattaag	atactcaata	atttggtgtg	tgatatcgct	gctaatactg	19800
taatctggga	ctacaaaaga	gaagccccag	cacatgtatc	tacaataggt	gtctgcacaa	19860
tgactgacat	tgccaagaaa	cctactgaga	gtgcttgctc	ttcacttact	gtcttggttg	19920
atggtagagt	ggaaggacag	gtagaccttt	ttagaaacgc	ccgtaatgg	gttttaataa	19980
cagaagggtc	agtcaaagg	ctaacacctt	caaagggacc	agcacaagct	agcgtcaatg	20040
gagtcacatt	aattggagaa	tcagtaaaaa	cacagttaa	ctactttaag	aaagtagacg	20100
gcattattca	acagttgcct	gaaacctact	ttactcagag	cagagactta	gaggatttta	20160
agcccagatc	acaaatggaa	actgactttc	tcgagctcgc	tatggatgaa	ttcatacagc	20220
gatataagct	cgagggctat	gccttcgaac	acatcgttta	tggagatttc	agtcatggac	20280
aacttggcgg	tcttcattta	atgataggct	tagccaagcg	ctcacaagat	tcaccactta	20340
aattagagga	ttttatccct	atggacagca	cagtgaaaaa	ttacttcata	acagatgcgc	20400
aaacagggtc	atcaaaatgt	gtgtgttctg	tgattgatct	tttacttgat	gactttgtcg	20460
agataataaa	gtcacaagat	ttgtcagtga	tttcaaaagt	ggtaagggtt	acaattgact	20520
atgctgaaat	ttcattcatg	ctttgggtga	aggatggaca	tggtgaaacc	ttctacccaa	20580
aactacaagc	aagtcgagcg	tggcaaccag	gtgttgcgat	gcctaacttg	tacaagatgc	20640
aaagaatgct	tcttgaaaag	tgtgaccttc	agaattatgg	tgaaaatgct	gttataccaa	20700

aaggaataat	gatgaatgtc	gcaaagtata	ctcaactgtg	tcaatactta	aatacactta	20760
cttttagctgt	accctacaac	atgagagtta	ttcacttttg	tgctggctct	gataaaggag	20820
ttgcaccagg	tacagctgtg	ctcagacaat	ggttgccaac	tggcacacta	cttgctcgatt	20880
cagatcttaa	tgacttcgtc	tccgacgcat	attctacttt	aattggagac	tgtgcaacag	20940
tacatacggc	taataaatgg	gaccttatta	ttagcgatat	gtatgaccct	aggaccaaac	21000
atgtgacaaa	agagaatgac	tctaaagaag	ggtttttcac	ttatctgtgt	ggatttataa	21060
agcaaaaact	agccctgggt	ggttctatag	ctgtaaagat	aacagagcat	tcttggaatg	21120
ctgaccttta	caagcttatg	ggccatttct	catggtggac	agcttttggt	acaaatgtaa	21180
atgcatcatc	atcggaagca	tttttaattg	gggctaacta	tcttggaag	ccgaaggaaac	21240
aaattgatgg	ctataccatg	catgctaact	acattttctg	gaggaacaca	aatcctatcc	21300
agttgtcttc	ctattcactc	tttgacatga	gcaaatttcc	tcttaaatta	agagggaactg	21360
ctgtaatgtc	tcttaaggag	aatcaaatca	atgatatgat	ttattctctt	ctggaaaaag	21420
gtaggcttat	cattagagaa	aacaacagag	ttgtggtttc	aagtgatatt	cttggttaaca	21480
actaaacgaa	catgttttatt	ttcttattat	ttcttactct	cactagtggg	agtgaccttg	21540
accggtgcac	cacttttgat	gatgttcaag	ctcctaatta	cactcaacat	acttcatcta	21600
tgaggggggt	ttactatcct	gatgaaatth	ttagatcaga	cactctttat	ttactcagg	21660
atthattttct	tccattttat	tctaattgta	cagggtttca	tactattaat	catacgtttg	21720
gcaaccctgt	catacctttt	aaggatggta	tttatttttg	tgccacagag	aatcaaatg	21780
ttgtccgtgg	ttgggttttt	ggttctacca	tgaacaacaa	gtcacagtcg	gtgattatta	21840
ttaacaattc	tactaatggt	gttatacagag	catgtaactt	tgaattgtgt	gacaaccctt	21900
tctttgctgt	ttctaaaccc	atgggtacac	agacacatac	tatgatattc	gataatgcat	21960
ttaattgcac	tttcgagtac	atatctgatg	ccttttcgct	tgatgtttca	gaaaagtcag	22020
gtaattttta	acacttacga	gagtttgtgt	ttaaaaataa	agatgggttt	ctctatgttt	22080
ataagggtta	tcaacctata	gatgtagtct	gtgatctacc	ttctgggttt	aacactttga	22140
aacctatttt	taagttgcct	cttgggtatta	acattacaaa	tttttagagcc	attcttacag	22200
cctttttcacc	tgctcaagac	atthggggca	cgtcagctgc	agcctatttt	gttggctatt	22260
taaagccaac	tacattttatg	ctcaagtatg	atgaaaatgg	tacaatcaca	gatgctgttg	22320
attgttctca	aaatccactt	gctgaactca	aatgctctgt	taagagcttt	gagattgaca	22380
aaggaattta	ccagacctct	aatttcaggg	ttgttccctc	aggagatgtt	gtgagattcc	22440
ctaataattac	aaacttgtgt	ccttttgagg	aggtttttaa	tgctactaaa	ttcccttctg	22500
tctatgcatg	ggagagaaaa	aaaatttcta	attgtgttgc	tgattactct	gtgctctaca	22560
actcaacatt	tttttcaacc	tttaagtgtc	atggcgtttc	tgccactaag	ttgaatgatc	22620
tttgcttctc	caatgtctat	gcagattctt	ttgtagtcaa	gggagatgat	gtaagacaaa	22680
tagcgccagg	acaaactggg	gttattgctg	attataatta	taaattgcca	gatgatttca	22740
tgggttgtgt	ccttgcttgg	aatactagga	acattgatgc	tacttcaact	ggtaattata	22800
attataaata	taggtatctt	agacatggca	agcttaggcc	ccttgagaga	gacatatcta	22860
atgtgccttt	ctcccctgat	ggcaaaccct	gcaccccacc	tgctcttaat	tgttattggc	22920
cattaaatga	ttatgggttt	tacaccacta	ctggcattgg	ctaccaacct	tacagagttg	22980
tagtactttc	ttttgaactt	ttaaatgcac	cggccacggg	ttgtggacca	aaattatcca	23040
ctgaccttat	taagaaccag	tgtgtcaatt	ttaatthtaa	tggactcact	ggtactgggt	23100
tgttaactcc	ttcttcaaag	agatttcaac	catttcaaca	atthggccgt	gatgtttctg	23160
atthtactga	ttccgttcga	gatcctaaaa	catctgaaat	attagacatt	tcaccttgcc	23220
ccttttggggg	tgtaagtgtg	attacacctg	gaacaaatgc	ttcatctgaa	gttgctgttc	23280
tatatcaaga	tgthaaactgc	actgatgttt	ctacagcaat	tcattgcagat	caactcacac	23340
cagcttggcg	catatattct	actggaaaca	atgtattcca	gactcaagca	ggctgtctta	23400
taggagctga	gcatgtcgac	acttcttatg	agtgcgacat	tcctattgga	gctggcattt	23460
gtgctagtta	ccatacagtt	tctttattac	gtagtactag	ccaaaaatct	attgtggctt	23520
atactatgtc	tttaggtgct	gatagttcaa	ttgcttactc	taataacacc	attgctatac	23580
ctactaaactt	ttcaattagc	attactacag	aagtaatgcc	tgthttctatg	gctaaaacct	23640
ccgtagattg	taatattgtac	atctgcggag	attctactga	atgtgctaatt	ttgcttctcc	23700
aatatggtag	ccttttgaca	caactaaatc	gtgcactctc	aggtattgct	gctgaacagg	23760
atcgcaacac	acgtgaagtg	ttcgtctcaag	tcaaacaat	gtacaaaacc	ccaactttga	23820
aatatthttg	tggtthttat	ttttcacaaa	tattacctga	ccctctaaag	ccaactaaga	23880
ggtctthttat	tgaggacttg	ctctthtaata	agggtgacact	cgctgatgct	ggcttcatga	23940
agcaatatgg	cgaatgccta	ggtgatatta	atgctagaga	tctcatttgt	gcgcagaagt	24000
tcaatggact	tacagtgttg	ccacctctgc	tactgatga	tatgattgct	gcctacactg	24060
ctgctctagt	tagtggtact	gccactgctg	gatggacatt	tggtgctggc	gctgctcttc	24120
aaataccttt	tgctatgcaa	atggcatata	ggttcaatgg	cattggagtt	acccaaaatg	24180
ttctctatga	gaaccaaaaa	caaatcgcca	accaatthaa	caaggcgatt	agtcaaattc	24240
aagaatcact	tacaacaaca	tcaactgcat	tgggcaagct	gcaagacgtt	gttaaccaga	24300
atgctcaagc	attaaacaca	cttgthtaaac	aacttagctc	taatthttgg	gcaatthcaa	24360

gtgtgctaaa	tgatatcctt	tcgcgacttg	ataaagtcga	ggcggaggta	caaattgaca	24420
ggttaattac	aggcagactt	caaagccttc	aaacctatgt	aacacaacaa	ctaatacagg	24480
ctgctgaaat	cagggcttct	gctaatactg	ctgctactaa	aatgtctgag	tgtgttcttg	24540
gacaatcaaa	aagagttgac	ttttgtggaa	agggtacca	ccttatgtcc	ttcccacaag	24600
cagccccgca	tggtgttgtc	ttcctacatg	tcacgtatgt	gccatcccag	gagaggaact	24660
tcaccacagc	gccagcaatt	tgtcatgaag	gcaaagcata	cttccctcgt	gaagggtgtt	24720
ttgtgtttta	tggcacttct	tggtttatta	cacagaggaa	cttcttttct	ccacaaataa	24780
ttactacaga	caatacattt	gtctcaggaa	attgtgatgt	cgttattggc	atcattaaca	24840
acacagttta	tgatcctctg	caacctgagc	ttgactcatt	caaagaagag	ctggacaagt	24900
acttcaaaaa	tcatacatca	ccagatgttg	atcttggcga	catttcaggc	attaacgctt	24960
ctgtcgtcaa	cattcaaaaa	gaaattgacc	gcctcaatga	ggtcgctaaa	aattttaatg	25020
aatcactcat	tgaccttcaa	gaattgggaa	aatatgagca	atatattaaa	tggccttggt	25080
atgtttggct	cggcttcatt	gctggactaa	ttgccatcgt	catggttaca	atcttgcttt	25140
gttgcatgac	tagttgttgc	agttgcctca	aggggtgatg	ctcttggttg	tcttgctgca	25200
agtttgatga	ggatgactct	gagccagttc	tcaagggtgt	caaattacat	tacacataaa	25260
cgaacttatg	gatttgttta	tgagattttt	tactcttgga	tcaattactg	cacagccagt	25320
aaaaattgac	aatgcttctc	ctgcaagtac	tgttcatgct	acagcaacga	taccgctaca	25380
agcctcactc	cctttcggat	ggcttgttat	tggcgttgca	tttcttgctg	tttttcagag	25440
cgctaccaaa	ataattgcgc	tcaataaaaag	atggcagcta	gccctttata	agggttcca	25500
gttcatttgc	aatttactgc	tgctatttgt	taccatctat	tcacatcttt	tgttgctcgc	25560
tgcaggatatg	gaggcgcaat	ttttgtacct	ctatgccttg	atatattttc	tacaatgcat	25620
caacgcatgt	agaattatta	tgagatgttg	gctttgttgg	aagtgcaaat	ccaagaaccc	25680
attactttat	gatgccaaact	actttgtttg	ctggcacaca	cataactatg	actactgtat	25740
accatataac	agtgtcacag	atacaattgt	cgttactgaa	ggtgacggca	tttcaacacc	25800
aaaactcaaa	gaagactacc	aaattggtgg	ttattctgag	gataggcact	cagggtgtta	25860
agactatgtc	gttgtagatg	gctatttcac	cgaagtttac	taccagcttg	agtctacaca	25920
aattactaca	gacactggta	ttgaaaatgc	tacattcttc	atctttaaca	agcttggtta	25980
agaccaccg	aatgtgcaaa	tacacacaa	cgacggctct	tcaggagttg	ctaataccagc	26040
aatggatcca	atttatgatg	agccgacgac	gactactagc	gtgcctttgt	aagcacaaga	26100
aagtgagtac	gaacttatgt	actcattcgt	ttcggaagaa	acaggtagct	taatagttaa	26160
tagcgtactt	ctttttcttg	ctttcgtggg	attcttgcta	gtcacactag	ccatccttac	26220
tgcgcttcga	ttgtgtgcgt	actgctgcaa	tattgttaac	gtgagtttag	taaaaccaac	26280
ggtttacgtc	tactcgcgtg	ttaaaaatct	gaactcttct	gaaggagttc	ctgatcttct	26340
ggtctaaacg	aactaactat	tattattatt	ctgtttggaa	ctttaacatt	gcttatcatg	26400
gcagacaacg	gtactattac	cgttgaggag	cttaaacac	tcctggaaca	atggaacct	26460
gtaataggtt	tcctattcct	agcctggatt	atgttactac	aatttgccta	ttctaatacg	26520
aacaggtttt	tgtacataat	aaagcttggt	ttcctctggc	tcttggtggc	agtaaacact	26580
gcttggtttg	tgcttgctgc	tgtctacaga	attaattggg	tgactggcgg	gattgogatt	26640
gcaatggctt	gtattgtagg	cttgatgtgg	cttagctact	tcgttgcttc	cttcaggctg	26700
tttgctcgt	cccgtcfaat	gtgggtcattc	aaccagaaa	caaacattct	tctcaatgtg	26760
cctctccggg	ggacaattgt	gaccagaccg	ctcatggaaa	gtgaacttgt	cattgggtgct	26820
gtgatcattc	gtgggtcactt	gcgaatggcc	ggacactccc	tagggcgctg	tgacattaag	26880
gacctgccaa	aagagatcac	tgtggctaca	tcacgaacgc	tttcttatta	caaattagga	26940
gcgtcgcagc	gtgtaggcac	tgattcaggt	tttgctgcat	acaaccgcta	ccgtattgga	27000
aactataaat	taaatacaga	ccacgccggg	agcaacgaca	atattgcttt	gctagtacag	27060
taagtgacaa	cagatgtttc	atcttgttga	cttccaggtt	acaatagcag	agatattgat	27120
tatcattatg	aggactttca	ggattgctat	ttggaatctt	gacgttataa	taagttcaat	27180
agtgagacaa	ttatttaagc	ctctaactaa	gaagaattat	tcggagttag	atgatgaaga	27240
acctatggag	ttagattatc	cataaaaacg	acatgaaaat	tattctcttc	ctgacattga	27300
ttgtatttac	atcttgcgag	ctatatcact	atcaggagtg	tgttagaggt	acgactgtac	27360
tactaaaaga	accttgccca	tcaggaacat	acgagggcaa	ttcaccattt	cacctcttg	27420
ctgacaataa	atttgacta	acttgacta	gcacacactt	tgcttttgct	tgtgctgacg	27480
gtactcgaca	tacctatcag	ctgcgtgcaa	gatcagtttc	acaaaaactt	ttcatcagac	27540
aagaggaggt	tcaacaagag	ctctactcgc	cactttttct	cattgttgct	gctctagtat	27600
ttttaatact	ttgcttcacc	attaagagaa	agacagaatg	aatgagctca	ctttaattga	27660
cttctatttg	tgctttttag	cctttctgct	attccttggt	ttaataatgc	ttattatatt	27720
ttggttttca	ctcgaaatcc	aggatctaga	agaaccttgt	accaaagtct	aaacgaacat	27780
gaaacttctc	attgttttga	cttgatattc	tctatgcagt	tgcatatgca	ctgtagtaca	27840
gcgctgtgca	tctaataaac	ctcatgtgct	tgaagatcct	tgtaaggtag	aacactaggg	27900
gtaatactta	tagcactgct	tggttttggt	ctctaggaaa	ggttttacct	tttcatagat	27960
ggcacactat	ggttcaaaca	tgcacaccta	atgttactat	caactgtcaa	gatccagctg	28020

```

gtggtgcgct tatagctagg tggttggtacc ttcattgaagg tcaccaaact gctgcattta 28080
gagacgtact tggtgtttta aataaacgaa caaatataaa tgtctgataa tggaccccaa 28140
tcaaaccaac gtagtgcccc ccgcattaca tttggtggac ccacagattc aactgacaat 28200
aaccagaatg gaggacgcaa tggggcaagg ccaaaacagc gccgacccca aggtttaccc 28260
aataatactg cgtcttggtt cacagctctc actcagcatg gcaaggagga acttagattc 28320
cctcgaggcc agggcgttcc aatcaacacc aatagtggtc cagatgacca aattggctac 28380
taccgaagag ctacccgacg agttcgtggt ggtgacggca aaatgaaaga gctcagcccc 28440
agatggtact tctattacct aggaactggc ccagaagctt cacttcctta cggcgctaac 28500
aaagaaggca tcgtatgggt tgcaactgag ggagccttga atacacccaa agaccacatt 28560
ggcaccgcga atcctaataa caatgctgcc accgtgctac aacttcctca aggaacaaca 28620
ttgccaaaag gcttctacgc agaggggaagc agaggcggca gtcaagcctc ttctcgctcc 28680
tcatcacgta gtcgcggtaa ttcaagaaat tcaactcctg gcagcagtag gggaaattct 28740
cctgctcgaa tggctagcgg aggtggtgaa actgccctcg cgctattgct gctagacaga 28800
ttgaaccagc ttgagagcaa agtttctggt aaaggccaac aacaacaagg ccaaactgtc 28860
actaagaaat ctgctgctga ggcattctaa aagcctcgcc aaaaacgtac tgccacaaaa 28920
cagtacaacg tcaactcaagc atttgggaga cgtggtccag aacaaaccca aggaaatttc 28980
ggggaccaag acctaatacag acaaggaact gattacaaac attggccgca aattgcacaa 29040
tttgctccaa gtgcctctgc attctttgga atgtcacgca ttggcatgga agtcacacct 29100
tcgggaacat ggctgactta tcatggagcc attaaattgg atgacaaaga tccacaattc 29160
aaagacaacg tcatactgct gaacaagcac attgacgcat acaaaacatt cccaccaaca 29220
gagcctaaaa aggacaaaaa gaaaaagact gatgaagctc agcctttgcc gcagagacaa 29280
aagaagcagc ccactgtgac tcttcttctt gcggctgaca tggatgattt ctccagacaa 29340
cttcaaaatt ccatgagtgg agcttctgct gattcaactc aggcataaac actcatgatg 29400
accacacaag gcagatgggc tatgtaaacg ttttcgcaat tccgtttacg atacatagtc 29460
tactcttggt cagaatgaat tctcgtaact aaacagcaca agtaggttta gttaacttta 29520
atctcacata gcaatcttta atcaatgtgt aacattaggg aggacttgaa agagccacca 29580
cattttcatc gaggccacgc ggagtacgat cgaggggtaca gtgaataatg ctaggggagag 29640
ctgcctatat ggaagagccc taatgtgtaa aattaatttt agtagtgcta tccccatgtg 29700
attttaatag cttcttagga gaatgacaaa aaaaaaaaaa aaaaaaaaaa a 29751

```

WHAT IS CLAIMED IS:

1. Use of a siRNA for inactivating hepatitis C virus, wherein said siRNA consists of a first strand of SEQ ID NO: 1 and a second strand of SEQ ID NO: 2.

5

2. Use of a siRNA for inactivating hepatitis C virus, wherein said siRNA consists of a first strand of SEQ ID NO: 1 and a second strand of SEQ ID NO: 2, and wherein said siRNA further comprises a modification at the 2' position of at least one ribonucleotide.

10

3. The use of claim 2, wherein said modification is selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-modification.

4. The use of claim 3, wherein said fluoro-modification is a 2'-fluoro-modification or a 2',2'-difluoro-modification.

15

5. The use of any one of claims 2-4, wherein at least one pyrimidine of said siRNA is modified, and wherein said at least one pyrimidine is cytosine, a derivative of cytosine, uracil or a derivative of uracil.

20

6. The use of any one of claims 2-5, wherein both strands of said siRNA contain at least one modified nucleotide.

7. A siRNA comprising at least one modified ribonucleotide, wherein said siRNA is resistant to RNase and retains the ability to inhibit hepatitis C virus (HCV) replication, and wherein said siRNA consists of a first strand of SEQ ID NO: 1 and a second strand of SEQ ID NO: 2.

25

8. The siRNA of claim 7, wherein said siRNA is modified at the 2' position of the at least one ribonucleotide.

30

9. The siRNA of claim 7 or 8, wherein the modification is selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-modification.

10. The siRNA of claim 9, wherein said fluoro-modification is a 2'-fluoro-modification or a 2',2'-difluoro-modification.
- 5 11. The siRNA of any one of claims 7-10, wherein at least one pyrimidine of said siRNA is modified, and wherein said at least one pyrimidine is cytosine, a derivative of cytosine, uracil or a derivative of uracil.
12. The siRNA of any one of claims 7-11, wherein both strands of the siRNA
10 contain modified nucleotides.
13. A double-stranded RNA molecule that inhibits replication of hepatitis C virus (HCV), wherein said double-stranded RNA consists of a first strand of SEQ ID NO: 1 and a second strand of SEQ ID NO: 2.
15
14. A vector comprising the RNA molecule of claim 13.
15. The vector of claim 14, wherein the first strand of said double-stranded RNA molecule is operably linked to a first promoter and wherein the second strand of said
20 double-stranded RNA molecule is operably linked to a second promoter.
16. The vector of claim 15, wherein said first and second promoters are selected from the group consisting of U6 and H1.
- 25 17. The vector of claim 15 or 16 wherein said first and second promoters are the same.
18. The vector of claim 14, wherein the first and second strands of said RNA molecule are under the control of a single promoter.
30
19. The vector of claim 18, wherein said single promoter is selected from the group consisting of U6 and H1.

20. A host cell comprising the vector of any one of claims 14-19.


21. Use of the vector of any one of claims 14-19 for inhibiting replication of hepatitis C virus (HCV) in cells carrying HCV.

5

22. Use of a composition comprising the RNA molecule of claim 13 and a pharmaceutically acceptable carrier for treating hepatitis C virus infection.

23. Use of the vector of any one of claims 14-19 for treating Hepatitis C virus
10 infection.

Fig. 1. The Sequence and Secondary Structure of 5'UTR of HCV Genome.



The region where siRNAs was designed is boxed.
The sequence of the 21-bp siRNA₅ is shown below.

	286	304
siRNA ₅	5'-GUACUGCCUGAUAGGGUGCUU UUCAUGACGGACUAUCCCACG-5'	
GL2	5'-CGUACGCGGAUACUUCGAUU UUGCAUGCGCCUUAUGAAGCU-5'	
GL3	5'-CUUACGCUGAGUACUUCGAUU UUGAAUGCGACUCAUGAAGCU--5'	
SIN	5'-AUCUCUACGGUGGUCCUAAUU UUUAGAGAUGCCACCAGGAUU--5'	

2/24
Fig. 2

	Domain	sequence (NN-N19-NN)	Position		
5U8	5'UTR	cc-CUGUGAGGAACUACUGUCU-uc	45-63	sense	CUGUGAGGAACUACUGUCUUC
				antisense	AGACAGUAGUUCCUCACAGGG
5U9		ua-CUGUCUUCACGCAGAAAGC-gu	58-76	sense	CUGUCUUCACGCAGAAAGCGU
				antisense	GCUUUCUGCGUGAAGACAGUA
5U10		cg-AGACUGCUAGCCGAGUAGU-gu	244-262	sense	AGACUGCUAGCCGAGUAGUGU
				antisense	ACUACUCGGCUAGCAGUCUCG
C1	Core	ga-AUCCUAAACCUCAAAGAAA-aa	352-370	sense	AUCCUAAACCUCAAAGAAAA
antisense				UUUCUUUGAGGUUUAGGAUUC	
C2		gg-UCAGAUUCGUCGGUGGAGUU-ua	425-443	sense	UCAGAUUCGUCGGUGGAGUUUA
				antisense	AACUCCACCGACGAUCUGACC
C3		gg-UAAGGUCAUCGAUACCCUC-ac	701-719	sense	UAAGGUCAUCGAUACCCUCAC
				antisense	GAGGGUAUCGAUGACCUUACC
C4		ac-GGCGUGAACUAUGCAACAG-gg	822-840	sense	GGCGUGAACUAUGCAACAGGG
				antisense	CUGUUGCAUAGUUCACGCCGU
C5		cc-GGUUGCUCUUUUCUAUCU-uc	852-870	sense	GGUUGCUCUUUUCUAUCUUC
				antisense	AGAUAGAAAAGGAGCAACCGG
5B1	NS5B	gc-UCUUCAUACGGAUUCCAAU-ac	8163-8181	sense	UCUUCAUACGGAUUCCAAUAC
antisense				AUUGGAAUCCGUAUGAAGAGC	
5B2		ca-UACGGAUUCCAAUACUCUC-cu	8167-8187	sense	UACGGAUUCCAAUACUCUCCU
				antisense	GAGAGUAUUGGAAUCCGUAUG
5B3		uu-UGACUCAACGGUCACUGAG-aa	8270-8288	sense	UGACUCAACGGUCACUGAGAA
				antisense	CUCAGUGACCGUUGAGUCAAA
5B4		cc-UUCACGGAGGCUAUGACUA-ga	8613-8631	sense	UUCACGGAGGCUAUGACUAGA
				antisense	UAGUCAUAGCCUCCGUGAAGG
5B5		au-ACGACUUGGAGUUGAUAAAC-au	8671-8689	sense	ACGACUUGGAGUUGAUAACAU
				antisense	GUUAUCAACUCCAAGUCGUAU
5B6		au-UCCUGGCUAGGCAACAUCA-uc	8817-8835	sense	UCCUGGCUAGGCAACAUCAUC
				antisense	UGAUGUUGCCUAGCCAGGAAU
5B7		uu-GUGGCAAGUACCUCUCAA-cu	9160-9178	sense	GUGGCAAGUACCUCUCAAACU
				antisense	UUGAAGAGGUACUUGCCACAA
5B8		au-GUGGUGCCUACUCCUACUU-uc	9317-9335	sense	GUGGUGCCUACUCCUACUUUC
				antisense	AAGUAGGAGUAGGCACCACAU
3U1	3'UTR	cu-UUGGUGGCUCCAUCUUAGC-cc	9506-9524	sense	UUGGUGGCUCCAUCUUAGCCC
antisense				GCUAAGAUGGAGCCACCAAAG	
3U2		gu-CACGGCUAGCUGUGAAAGG-uc	9531-9549	sense	CACGGCUAGCUGUGAAAGGUC
				antisense	CCUUUCACAGCUAGCCGUGAC
3U3		ag-CCGCUUGACUGCAGAGAGU-gc	9558-9576	sense	CCGCUUGACUGCAGAGAGUGC
				antisense	ACUCUCUGCAGUCAAGCGGCU

Fig. 3

1 ttattagggt ttacctacc caggaaaagc caaccaacct cgatctcttg tagatctgtt
 61 ctctaaacga actttaaact ctgtgtagct gtcgctcggc tgcagccta gtgcacctac
 121 gcagtataaa caataataaa ttctactgtc gttgacaaga aacgagtaac tcgtccctct
 181 tctgcagact gcttacgggt tcgtccgtgt tgcagtcgat catcagcata cctaggtttc
 241 gtccgggtgt gaccgaaagg taagatggag agcctgttc ttggtgtcaa cgagaaaaca
 301 caogtccaac tcagttigcc tgccttcag gtiagagacg tgctagtgcg tggcttcggg
 361 gactctgtgg aagaggccct atcggaggca cgtgaacacc tcaaaaatgg cacttgtgtt
 421 ctagtagagc tggaaaaagg cgtactgccc cagcttgaac agccctatgt gttcattaaa
 481 cgttctgatg ccttaagcac caatcacggc cacaaggctg ttgagctggt tgcagaaatg
 541 gacggcattc agtacggctg tagcgggtata acactgggag tactcgtgcc acatgtgggc
 601 gaaaccccaa ttgcataccg caatgttctt ctctgtaaga acgtaataa gggagccggg
 661 ggtcatagct atggcatcga tctaaagtct tatgacttag gtgacgagct tggcactgat
 721 cccattgaag attatgaaca aaactggaac actaagcatg gcagtgggtc actccgtgaa
 781 ctactcgtg agctcaatgg aggtgcagtc actcgtctatg tcgacaacaa ttctgtggc
 841 ccagatgggt accctctga ttgcatacaa gatttctcg cagcgcggg caagtcaatg
 901 tgcactctt cgaacaact tgattacatc gagtgaaga gaggtgtcta ctgctgccgt
 961 gaccatgagc atgaaatgc ctggttact gagcgctctg ataagagcta cgagcaccag
 1021 acacccttcg aaattaagag tgccaagaaa ttgacactt tcaaagggga atgoccaaag
 1081 ttgtgtttc ctcttaactc aaaagtcaaa gtcatcaac cagtggtga aaagaaaaag
 1141 actgagggtt tcatggggcg tatacgctct gtgtaccctg ttgcatctcc acaggagtgt
 1201 aacaatatgc actgtctac ctgatgaaa tgaatcatt gcatgaagt tcatggcag
 1261 acgtgcgact ttctgaaagc cacttgtgaa cattgtggca ctgaaaattt agttattgaa
 1321 ggacctacta catgtgggta cctacctact aatgctgtag tgaatgccc atgtcctgcc
 1381 tgtcaagacc cagagattgg acctgagcat agtgttcag attatcaca ccaactcaac
 1441 attgaaactc gactccgcaa gggaggtagg actagatgtt ttggaggctg tgtgttgcc
 1501 tatgttggct gctataataa gcgtgcctac tgggttcctc gtgctagtgc tgatattggc
 1561 tcaggccata ctggcattac tggtgacaat gtggagacct tgaatgagga tctcctgag
 1621 atactgagtc gtgaacgtgt taacattaac attgtggcg atttcattt gaatgaagag
 1681 gttgccatca tttggcatc ttctctgct tctacaagt ccttatga cactataaag
 1741 agtcttgatt acaagtctt caaaaccatt gttgagctct gcgtaacta taaagtacc
 1801 aagggaagc ccgtaaaagg tgcttgaac attggacaac agagatcagt ttaacacca
 1861 ctgtgtggtt tccctcaca ggctgctggt gttatcagat caattttgc gcgcacact
 1921 gatgcagcaa accactcaat tctgatttg caaagagcag ctgtcaccat actgatggt
 1981 atttctgaac agtcattacg tctgtcgac gccatgggtt atactcaga cctgctcacc
 2041 aacagtgtca ttattatggc atatgtaact ggtggtcttg tacaacagac ttctcagtgg
 2101 ttgtctaac tttgggcac tactgttgaa aaactcaggc ctatcttga atggattgag
 2161 gcgaaactta gtgcaggagt tgaattctc aaggatgctt gggagattct caaatttctc
 2221 attacagggt ttttgacat cgtcaagggt caaatacagg ttgctcaga taacatcaag
 2281 gattgtgtaa aatgctcat tgatgtgtt aacaaggcac tcgaaatgtg cattgatcaa
 2341 gtcactatcg ctggcgcaaa gttgcgatca ctcaacttag gtgaagctt catcgctcaa
 2401 agcaagggac ttaccgtca gtgtatagc ggcaaggagc agctgcaact actcatgcct
 2461 cttaggcac caaaagaagt aaccttctt gaagggtatt cacatgacac agtactacc
 2521 tctgaggagg ttgttctcaa gaacggtgaa ctggaagcac tcgagacgcc cgttgatagc
 2581 ttacaaatg gagctatcgt cggcacacca gtctgtgtaa atggcctcat gctcttagag
 2641 attaggaca aagaacaata ctgcgattg tctcctggt tactggctac aaacaatgtc
 2701 tttcgcttaa aaggggggtgc accaattaaa ggtgtaacct ttggagaaga tactgtttgg
 2761 gaagttcaag gttacaagaa tgtgagaatc acatttgagc ttgatgaacg tttgacaaa

2821 gtgcttaatg aaaagtgtc tgtctacact gttgaatccg gtaccgaagt tactgagttt
 2881 gcatgtgtg tagcagaggc tgtgtgaag actttacaac cagttctga tctcctacc
 2941 aacatgggtg ttgatctga tgagtggagt gtagctacat tctactatt tgatgatgt
 3001 ggtgaagaaa actttcatc acgtatgtat tttccttt accctccaga tgaggaagaa
 3061 gaggacgatg cagagtgtga ggaagaagaa attgatgaaa cctgtgaaca tgagtacggt
 3121 acagaggatg attatcaagg tctccctctg gaatttggg cctcagctga aacagttcga
 3181 gttgaggaag aagaagagga agactggctg gatgatacta ctgagcaatc agagattgag
 3241 ccagaaccag aacctacacc tgaagaacca gtaatacagt ttactggta tttaaaactt
 3301 actgacaatg ttgccattaa atgtgtgac atcgtaagg aggcacaaag tgctaactct
 3361 atggtgattg taaatgtgc taacatacac ctgaaacatg gtgggtggtg agcaggtgca
 3421 ctcaacaagg caaccaatgg tgccatgcaa aaggagagtg atgattacat taagctaaat
 3481 ggccctctta cagtaggagg gtctgtttg cttctggac ataacttgc taagaagtgt
 3541 ctgcatgtg ttggacctaa cctaaatgca ggtgaggaca tccagctct taaggcagca
 3601 tatgaaaatt tcaattcaca ggacatctta ctgacccat tgtgtcagc aggcatttt
 3661 ggtgctaaac cacttcagtc ttacaagtg tgcgtgcaga cggttcgtac acaggtttat
 3721 attgcagtca atgacaaagc tctttatgag caggtgtca tggattatc tgataacctg
 3781 aagcctagag tggaagcacc taaacaagag gagccacca acacagaaga ttccaaaact
 3841 gaggagaaat ctgtctaca gaagcctgtc gatgtgaagc caaaaattaa ggctgcatt
 3901 gatgaggta ccacaacact ggaagaaact aagttctta ccaataagtt actctgttt
 3961 gctgatatca atggtagct ttaccatgat tctcagaaca tgccttagagg tgaagatatg
 4021 tcttctctg agaaggatgc accctacatg gtaggtgat ttatcactag tggatgatac
 4081 actgtgttg taataccctc caaaaaggct ggtggcacta ctgagatgct ctcaagagct
 4141 ttgaagaaag tgccagtga tgagtatata accacgtacc ctggacaagg atgtgctggt
 4201 tatacacttg aggaagctaa gactgctctt aagaaatgca aatctgcatt ttatgtacta
 4261 ccttcagaag cacctaagc taaggaagag attctaggaa ctgtatctg gaatttgaga
 4321 gaaatgctg ctcatgctga agagacaaga aaattaatgc ctatatgcat ggatgttaga
 4381 gccataatgg caaccatcca acgtaagtat aaaggaatta aaattcaaga gggcatcgtt
 4441 gactatggg tccgattctt ctttatact agtaagagc ctgtagctc tattattacg
 4501 aagctgaact ctctaaatga gccgctgtc acaatgcaa ttggtatgt gacacatggt
 4561 tttaacttg aagaggctgc ggcgtgatg cgttctctta aagctctgc cgtagtgtca
 4621 gtatcatcac cagatgctgt tactacatat aatggatacc tctctctc atcaaagaca
 4681 tctgaggagc actttgtaga aacagttct ttggctggct ctacagaga ttggtcctat
 4741 tcaggacagc gtacagagt aggtgtgaa ttcttaagc gtggtgacaa aattgtgtac
 4801 cacactctgg agagccccgt cgagtticat ctgacgggt aggtctttc acttgacaaa
 4861 ctaaagagtc tctatccct ggggagggt aagactataa aagtgtcac aactgtggac
 4921 aacactaatc tccacacaca gcttggat atgtctatga catatggaca gcagtttgt
 4981 ccaacatact tggatggtg tgatgtaca aaaattaaac ctcatgaaa tcatgagggt
 5041 aagactttct ttgtactacc tagtgatgac acactacgta gtgaagctt cgagtactac
 5101 catactctg atgagagtt tcttggtagg tacatgtctg cttaaacca cacaagaaa
 5161 tggaaattc ctcaagttg ttggttaact tcaattaaat gggctgataa caattgtat
 5221 ttgtctagt tttatagc acttcaacag ctgaagtca aattcaatgc accagcact
 5281 caagaggctt attatagagc ccgtgctggt gatgctgcta actttgtgc actcatactc
 5341 gcttacagta ataaaactgt tggcgagctt ggtgatgtca gagaaactat gacctctt
 5401 ctacagcatg ctaatttga atctgcaaag cgagttctta atgtggtgtg taaacattgt
 5461 ggtcagaaaa ctactacctt aacgggtgta gaagctgtga tgtatatgg tactctatct
 5521 tatgataatc ttaagacagg ttttccatt ccatgtgtgt gtggtcgtga tgcacacaa
 5581 tatctagtac aacaagagtc ttctttgtt atgatgtctg caccacctgc tgagtataaa
 5641 ttacagcaag gtacattct atgtgcgaat gactacactg gtaactatca gtgtggtcat
 5701 tacactcata taactgctaa ggagaccctc tatcgtattg acggagctca ccttacaag
 5761 atgtcagagt acaaaggacc agtgactgat gtttctaca aggaaacatc ttactatac
 5821 accatcaagc ctgtgtcgt taaactcgat ggagtactt acacagagat tgaacaaaa
 5881 ttgatgggt attataaaa ggataatgct tactatacag agcagctat agaccttga
 5941 ccaactcaac cattacaaa tgcgagttt gataatttca aactcacatg tttaacaca
 6001 aaatttctg atgattaaa tcaaatgaca ggcttcacaa agccagcttc acgagagcta
 6061 tctgtcacat tctcccaga ctgaatggc gatgtagtgg ctattgacta tagacactat
 6121 tcagcgagtt tcaagaaagg tgctaaatta ctgcataagc caattgttg gcacattaac

6181 caggctacaa ccaagacaac gtcaaacca aacacttggg gttacgttg tcttggagt
6241 acaaagccag tagatacttc aaattcattt gaagttctgg cagtagaaga cacacaagga
6301 atggacaatc ttgcttgtga aagtcaacaa cccacctctg aagaagtagt ggaaaatcct
6361 accatacaga aggaagtcac agagtgtgac gtgaaaacta ccgaagttgt aggcaatgtc
6421 atacttaaac catcagatga aggtgttaaa gtaacacaag agttaggta tgaggatctt
6481 atggctgctt atgtggaaaa cacaagcatt accattaaga aacctaata gcttcacta
6541 gccttaggtt taaaaacaat tgcactcat ggtattgctg caattaatag tgttccttgg
6601 agtaaaattt tggcttatgt caaaccttc ttaggacaag cagcaattac aacatcaaat
6661 tgcgctaaga gattagcaca acgtgtgttt aacaattata tgccttatgt gtttacatta
6721 ttgtccaat tgtgtacttt tactaaaagt accaattcta gaatiagagc ttactacct
6781 acaactattg ctaaaaatag tgttaagagt gttgctaaat taigtgttga tgcgggcatt
6841 aattatgiga agtcacccaa atttctaaa ttgtcacaac tgcctatgtg gctattgttg
6901 ttaagtattt gcttaggttc tctaactgtt gtaactgctg ctttgggtgt actcttatct
6961 aatttgggtg ctctcttta ttgtaatggc gttagagaat tgtatcttaa ttgcttaac
7021 gttactacta tggattctg tgaaggttct ttctctgca gcatttgtt aagtggatta
7081 gactcccttg attcttatcc agctctgaa accattcagg tgacgatttc atcgtacaag
7141 ctagacttga caattttagg tctggccgct gagtgggttt tggcatatat gttgtcaca
7201 aaattctttt atttattagg tcttcagct ataatgcagg tgttcttgg ctatttggct
7261 agtcatttca tcagcaattc ttggctcatg tggtttatca ttagtattgt acaaatggca
7321 ccggttctg caatggtag gatgtacac ttcttgcct cttctacta catatggaag
7381 agctatgttc atatcatgga tgggtgcacc tcttcgactt gcatgatgtg ctataagcgc
7441 aatcgtgcca cagcgttga gtgtacaact attgttaatg gcatgaagag atcttctat
7501 gtctatgcaa atggaggccg tggctctgc aagactcaca attggaattg tctcaattgt
7561 gacacatttt gcactggtag tacattcatt agtgatgaag ttgctcgtga ttgtcactc
7621 cagtttaaaa gaccaatcaa cctactgac cagtcacgt atattgttga tagtgttgc
7681 gtgaaaaatg gcgcttca cctctactt gacaaggctg gtcaaaagac ctatgagaga
7741 catccgtct cccatttgt caatttagac aatttagag ctaacaacac taaaggttca
7801 ctgcctatta atgtcatagt ttgatggc aagtccaaat gcgacgagtc tgccttaag
7861 tctgttctg tgtactacag tcagctgatg tgccaacctt ttctgtgtg tgaccaagct
7921 ctgtatcag acgttggaga tagtactgaa gttccgtta agatgttga tgcctatgtc
7981 gacaccttt cagcaacttt tagtgttct atggaaaaac ttaaggcact tgtgtctaca
8041 gctcacagcg agttagcaaa ggggttagct ttgatgggt tcttctac attcgtgtca
8101 gctgcccagc aagggtgtg tgataccgat gttgacacaa aggatgttat tgaatgtctc
8161 aaactttcac atcactctga cttagaagt acaggtgaca gttgaacaa ttcatgctc
8221 acctataata aggttgaata catgacgccc agagatctg gcgcatgtat tgactgtaat
8281 gcaaggcata tcaatgccc agtagcaaaa agtcacaatg ttactcat ctggaatgta
8341 aaagactaca tgtcttatc tgaacagctg cgtaaacaaa ttctagtgc tgccaagaag
8401 aacaacatac ctttagact aactgtgt acaactagac aggtgtcaa tgcataact
8461 actaaaatct cactcaaggg tggtaagatt gttagtact gtttaaaact tatgttaag
8521 gccacattat tgtgcttct tgcgtcattg gttgttata tcttatgcc agtacatata
8581 ttgtcaatcc atgatggta cacaatgaa atcattggtt acaaagccat tcaggatgg
8641 gtcactcgtg acatcattc tactgatgat tgtttgcaa ataaacatgc tggtttgac
8701 gcatggttta gccagcgtg tggttcatc aaaaatgaca aaagctgcc ttagtagct
8761 gctatcatta caagagagat tggttcata gtgcctggct taccgggtac tgtgctgaga
8821 gcaatcaatg gtgactctt gcatttcta cctcgtgtt ttagtgtgt tggcaacatt
8881 tgcacacac ctccaaact catgagat agtgattt ctacctctg ttgcgttct
8941 gctgctgagt gtacaattt taaggatgct atgggcaaac ctgtgccata ttgtatgac
9001 actaatttc tagagggtc tattcttat agtgagctc gtccagacac tcttatgtg
9061 ctatggatg gttccatcat acagtttct aacacttacc tggagggtc tgttagagta
9121 gtaacaactt ttgatgtga gtactgtaga catggtacat gcgaaaggc agaagtaggt
9181 atttgcctat ctaccagtgg tagatgggt ctaataatg agcattacag agctctatca
9241 ggagtittct gtggtgtga tgcgatgaat ctcatagcta acatcttct tctctgtg
9301 caacctgtg gtgcttga tgtgtctgt tcagtagtg ctggtgttat tattgccata
9361 ttggtgact gtgctgccta ctacttatg aaattcagac gtgttttgg tgagtacaac
9421 catgtgtg ctgctaagc actttgtt ttgatgtct tcaactact ctgtcggta
9481 ccagcttaca gcttctgcc gggagtctac tcagtcttt actgtactt gacattctat

9541 ttaccaatg atgtttcatt ctgggtcac ctcaatggt ttgcatgtt ttctctatt
9601 gtgcctttt ggataacagc aatctatgta ttctgtatt ctctgaagca ctgccattgg
9661 ttcttaaca actatcttag gaaaagagtc atgttaatg gagttacatt tagtaccttc
9721 gaggaggctg ctttgtgtac cttttgctc aacaaggaaa tgtacctaaa attgcgtagc
9781 gagacactgt tggcacttac acagtataac aggtatcttg ctctatataa caagtacaag
9841 tatttcagtg gagccttaga tactaccagc tatcgtgaag cagcttgctg ccacttagca
9901 aaggctctaa atgacttag caactcaggt gctgatgttc tctaccaacc accacagaca
9961 tcaatcactt ctgcigtct gcagagtgg tttaggaaaa tggcattccc gtcaggcaaa
10021 gttgaagggt gcatgtaca agtaacctgt ggaactacaa ctctaatgg attgtggttg
10081 gatgacacag tatactgtcc aagacatgtc attgcacag cagaagacat gcttaatcct
10141 aactatgaag atctgtcat tcgcaaatcc aaccatagct ttctgttca ggctggcaat
10201 gttaacttc gtgtattgg ccattctatg caaaattgtc tgcctaggct taaagttgat
10261 acttctaacc ctaagacacc caagtataaa ttgtccgta tccaacctgg tcaaacattt
10321 tcagttctag catgtacaa tggttacca tctgggttt atcagtgtgc catgagacct
10381 aatcatacca ttaaagggtc ttcttaat ggatcatgtg gtagtgttg tttaacatt
10441 gattatgatt gcgtgtctt ctgtatatg catcatatgg agctccaac aggagtacac
10501 gctggtactg acttagaagg taaattctat ggtccatttg ttgacagaca aactgcacag
10561 gctgcaggta cagacacaac cataacatta aatgttttg catggctgta tgcgtgtgt
10621 atcaatgggt atagggtgtt tctaataga ttaccacta cttgaatga ctttaacct
10681 gtggcaatga agtacaacta tgaaccttg acacaagatc atgtgacat attgggacct
10741 ctttctgctc aaacaggaat tggcgtctta gatatgtgtg ctgcttgaa agagctgctg
10801 cagaatggtg tgaatggtcg tactatcctt gtagcacta tttagaaga tgagttaca
10861 ccatttgatg ttgttagaca atgctctggt gtaccctcc aaggtaagt caagaaaatt
10921 gtaaggga ctcactatg gatgttta acttctga catcactatt gattctgtt
10981 caaagtacac agtggctact gttttctt gttacgaga atgcttctt gccatttact
11041 ctggtatta tggcaattgc tgcattgtc atgctgctg ttaagcataa gcacgcattc
11101 ttgtgctgt ttctgtacc ttctctgca acagttgctt acttaatat ggtctacatg
11161 cctgctagct ggggtgatgc tatcatgaca tggctgaat tggctgacac tagctgtct
11221 ggttataggc ttaaggattg tttatgtat gcttcagctt tagtttgtct tattctcatg
11281 acagctcgca ctgttatga tgatgctgt agacgtgtt ggacactgat gaatgtcatt
11341 acacttggtt acaaagtcta ctatggtaat gcttagatc aagctattc catgtgggccc
11401 ttagttatt ctgtaacctc taactatct ggtgtcgtta cgactatcat gttttagct
11461 agagctatag ttttgtgtg tttgagtat taccattgt tattattac tggcaacacc
11521 ttacagtga tcatgctgt ttattgttc ttaggctatt gttgctgctg ctacttggc
11581 ctttctgt tactcaaccg ttactcagg ctactcttg gtgttatga ctacttggc
11641 tctacacaag aatttaggta tatgaacct caggggctt tgcctctaa gagtagtatt
11701 gatgtttca agttaacat taagtgttg ggtattggag gtaaaccatg tatcaagggt
11761 gctactgtac agtctaaaat gtctgacgta aagtgcacat ctgtggtact gctctgggt
11821 ctcaacaac ttagagtaga gtcactct aaattgtgg cacaatgtgt acaactccac
11881 aatgatatt ttctgcaaa agacacaact gaagcttgc agaagaagg ttctctttg
11941 tctgtttgc tatccatgca ggggtgtga gacattaata ggtgtgcga ggaaatgctc
12001 gataaccgtg ctactctca ggctattgct tcagaattta gtctttacc atcatatgcc
12061 gcttatgcca ctgccagga ggctatgag caggctgtg ctaatggga ttctgaagtc
12121 gttctcaaaa agttaaagaa atcttgaat gtggctaaat ctgagttga ccgtgatgct
12181 gccatgcaac gcaagttgga aaagatggca gatcaggcta tgacccaat gtacaaacag
12241 gcaagatctg aggacaagag ggcaaaagta actagtcta tgcaacaat gctcttact
12301 atgcttagga agcttgataa tgatgcactt aacaacatta tcaacaatgc gcgtgatggt
12361 tgtgtccac tcaacatcat accattgact acagcagcca aactcatggt tgtgtccct
12421 gattatggta cctacaagaa cacttgtat ggtaacacct ttacatagc atctgcactc
12481 tgggaaatcc agcaagttgt tgatgcggat agcaagattg ttcaacttag tgaaattaac
12541 atggacaatt caccaaat ttgctggcct ctattgtta cagctctaag agccaactca
12601 gctgttaaac tacagaataa tgaactgagt ccagtagcac tacgacagat gtctgtgctg
12661 gctgttacca cacaacagc ttgtactgat gacaatgcac ttgcctacta taacaattcg
12721 aaggagggtg ggttgtgtc ggcattacta tcagaccacc aagatctcaa atgggctaga
12781 ttccctaaga gtgatgttac aggtacaatt tacacagaac tggaaccacc ttgtagggtt
12841 gtacagaca caccaaaagg gcctaaagt aaatactgt acttcatcaa aggcttaaac

12901 aacctaata gaggtatggt gctgggcagt ttagctgcta cagtacgtct tcaggctgga
12961 aatgctacag aagtacctgc caattcaact gtgcttctct tctgtgcttt tgcagtagac
13021 cctgctaaag catataagga ttacctagca agtggaggac aaccaatcac caactgtgtg
13081 aagatgttgt gtacacacac tggtagagga caggcaatta ctgtaacacc agaagctaac
13141 atggaccaag agtcctttgg tggtagctca tgtgtctgt atgttagatg ccacattgac
13201 catccaaatc ctaaaggatt ctgtgacttg aaaggtaagt acgtccaaat acctaccact
13261 tgtgctaatt acccagtggg tttaacactt agaaacacag tctgtaccgt ctgcggaatg
13321 tggaaagggt atggctgtag ttgtgaccaa ctccgcgaac cctgatgca gtctgcggat
13381 gcatcaacgt tttaaacgg gttgcgggtg taagtgcagc cgtcttaca cgtgcggca
13441 caggcactag tactgatgtc gtctacaggg ctttgatat ttacaacgaa aaagttgctg
13501 gttttgcaa gttcctaaaa actaattgct gtgccttcca ggagaaggat gaggaaggca
13561 atttattaga ctcttacttt gtagttaaga ggcatactat gtctaactac caacatgaag
13621 agactatta taacttggtt aaagattgtc cagcgggtgc tgtccatgac ttttcaagt
13681 ttagagtaga tggtagaatg gtaccacata tatcacgtca gcgtctaact aaatacacia
13741 tggctgattt agtctatgct ctacgtcatt ttgatgagg taattgtgat acattaaaag
13801 aaatactcgt cacatacaat tgctgtgat atgattattt caataagaag gattggtatg
13861 acttcgtaga gaactctgac atctacgcg tataatgctaa cttaggtgag cgtgtacgcc
13921 aatcattatt aaagactgta caattctgcg atgctatgag tgatgcaggc attgtaggcg
13981 tactgacatt agataatcag gatctaatg ggaactggta cgatttcggt gatttcgtac
14041 aagtagcacc aggtgcgga gttcctattg tggattcata ttactcattg ctgatgcca
14101 tctcacttt gactagggca ttggctgctg agtcccatat ggatgctgat ctgcgaaaac
14161 cacttattaa gtgggatttg ctgaaatag atttacgga agagagactt tgtctctcg
14221 accgttattt taaatattgg gaccagacat accatcccaa ttgtattaac tgtttggatg
14281 atagggtgat ccttcattgt gcaaacttta atgtgtatt ttctactgtg ttccaccta
14341 caagttttg accactagta agaaaaatat ttgtagatgg tttcctttt gttgtttcaa
14401 ctggatacca ttctgtgag ttaggagtgc tacataatca ggatgtaaac ttacatagct
14461 cgcgtctcag ttcaaggaa ctttagtgt atgctgctga tccagctatg catgcagctt
14521 ctggcaattt attgctagat aaacgcacta catgctttc agtagctgca ctaacaaaca
14581 atgttgctt tcaaactgtc aaaccggta attttaataa agactttat gactttgctg
14641 tgtctaaagg ttctttaag gaaggaagt ctgtgaact aaaacacttc ttcttgctc
14701 aggatggcaa cgctgctatc agtgattatg actattatcg ttataatcg ccaacaatgt
14761 gtgatatcag acaactccta ttctagtgtg aagttgtga taaatacttt gattgttacg
14821 atgggtggctg tattaatgcc aaccaagtaa tctgtaacaa tctggataaa tcagctgggt
14881 tccatttaa taaatgggtg aaggctagac ttattatga ctcaatgagt tatgaggatc
14941 aagatgcact ttctgcgtat actaagcgta atgtcatccc tactataact caaatgaatc
15001 ttaagtatgc cattagtgc aagaatagag ctgcaccgt agctgggtgc tctatctgta
15061 gtactatgac aaatagacag ttcatcaga aattattgaa gtcaatagcc gccactagag
15121 gagctactgt ggtaattgga acaagcaagt ttacgggtgg ctggcataat atgttaaaaa
15181 ctgtttacag tgatgtagaa actccacacc ttatgggttg ggattatcca aaatgtgaca
15241 gagccatgcc taacatgctt aggataatgg cctctctgt tcttgctcgc aaacataaca
15301 ctgtctgtaa ctatcacac cgtttctaca ggtagctaa cgagtgtgcg caagtattaa
15361 gtgagatggt catgtgtggc ggctcactat atgttaaacc aggtggaaca tcatccggtg
15421 atgtacaac tgcttatgct aatagtgtct ttacatttg tcaagctgtt acagccaatg
15481 taaatgcact tcttcaact gatggtaata agatagctga caagtatgtc cgcaatctac
15541 aacacaggct ctatgagtgt ctctatagaa atagggatgt tgatcatgaa ttctggatg
15601 agttttacgc ttacctgcgt aaacatttct ccatgatgat tctttctgat gatgccgttg
15661 tgtgctataa cagtaactat gcggcicaag gtttagtagc tagcattaag aactttaagg
15721 cagttcttta ttatcaaaat aatgtgttca tgtctgaggc aaaatgttg actgagactg
15781 acctactaa aggacctcac gaatttgct cacagcatac aatgctagt aaacaaggag
15841 atgattacgt gtacctgcct taccagatc catcaagaat attaggcgca ggctgtttg
15901 tcatgatata tgcataaca gatggtacac ttatgattga aaggttcgtg tcaactggcta
15961 ttgatgcta cccacttaca aaacatccta atcaggagta tgctgatgtc ttacttgt
16021 atttacaata cattagaaag ttacatgatg agcttactgg ccacatgttg gacatgtatt
16081 ccgtaatgct aactaatgat aacacctcac ggtactggga acctgagtt tatgaggcta
16141 tgtacacacc acatacagtc ttgcaggctg taggtgcttg tgtattgtgc aattcacaga
16201 ctactctcgt ttgcgggtgc tgtattagga gaccattcct atgttgcaag tctgctatg

16261 accatgtcat ttcaacatca cacaaattag tgtgtctgt taatccctat gtttgaatg
16321 ccccagggtg tgatgtcact gatgtgacac aactgtatct aggaggtag agctattatt
16381 gcaagtcaca taagcctccc attagtttcc catiatgtgc taatggtcag gttttgggt
16441 tatacaaaaa cacatgtgta ggcagtgaca atgtcactga ctcaatgcg atagcaacat
16501 gtgattggac taatgtctggc gattacatac ttgccaacac ttgtactgag agactcaagc
16561 ttttcgcagc agaaacgctc aaagccactg aggaacatt taagctgtca tatggtattg
16621 ccactgtacg cgaagtactc tctgacagag aatgtcatct tcatgggag gttggaaaac
16681 ctagaccacc attgaacaga aactatgtct ttactggta ccgtgtaact aaaaatagta
16741 aagtacagat tggagagtac accttgaaa aaggtgacta tggtagtct gttgtgtaca
16801 gaggtactac gacatacaag ttgaatgttg gtgattactt tgtgtigaca tctcacactg
16861 taatgccact tagtgacact actctagtgc cacaagagca ctatgtgaga attactggct
16921 tgtacccaac actcaacatc tcagatgagt ttctagcaa tgttgcaat tatcaaaagg
16981 tcggcatgca aaagtactct acactccaag gaccacctgg tactggtaag agtcattttg
17041 ccactggact tgctctctat taccatctg ctgcgatagt gtatcggca tgctctcatg
17101 cagctgttga tgcctatgt gaaaaggcat taaaatatt gcccatagat aaatgtagta
17161 gaatcatacc tgcgctgctg cgcttagagt gtttgataa attcaaagt aattcaacac
17221 tagaacagta tgtttctgc actgtaaatg cattgccaga aacaactgct gacattgtag
17281 tcttgatga aatctctatg gctactaatt atgactgag tttgtcaat gctagacttc
17341 gtgcaaaaca ctacgtctat attggcgatc ctgtcaatt accagcccc cgacattgc
17401 tgactaaagg cacactagaa ccagaatatt ttaattcagt gtgcagactt atgaaaacaa
17461 taggtccaga catgttctt ggaactgtc gccgtgtcc tgcgaaat gttgacactg
17521 tgagtcttt agttatgac aataagctaa aagcacacaa ggataagtca gctcaatgct
17581 tcaaatgtt ctacaaagg gttattacac atgatgttc atctgcaatc aacagacctc
17641 aaataggcgt tgaagagaa ttcttacac gcaatcctgc ttggagaaa gctgtttta
17701 tctcacctta taattcacag aacgctgtag ctcaaaaat cttaggattg cctacgcaga
17761 ctgttgattc atcacagggt tctgaatatg actatgtcat attcacacaa actactgaaa
17821 cagcacactc ttgtaatgtc aaccgcttca atgtggctat cacaagggca aaaattggca
17881 tttgtgcat aatgtctat agagatctt atgacaaact gcaattaca agtctagaaa
17941 taccagctc caatgtggct acattacaag cagaaaatgt aactggactt ttaaggact
18001 gtagtaagat cattactggt ctcatccta cacaggcacc tacacacctc agcgttgata
18061 taaagttcaa gactgaagga ttatgtgtg acataccagg cataccaag gacatgacct
18121 accgtagact catctctatg atgggtttca aaatgaatta ccaagtcaat ggttacccta
18181 atatgttat caccgcgaa gaagctattc gtcacgtcg tgcgtggatt ggcttgatg
18241 tagagggtg tcatgcaact agagatgctg tgggtactaa cctacctctc cagctaggat
18301 ttctacagg ttttaactta gtagctgtac cgactggta tttgacact gaaaataaca
18361 cagaattcac cagagtaat gcaaacctc caccaggta ccagttaaa catctatac
18421 cactcatgta taaaggctg ccttgaatg tagtgctat taagatagta caaatgtca
18481 gtgatacact gaaaggattg tcagacagag tctgttctg ccttgggag catggcttg
18541 agcttacatc aatgaagtac ttgtcaaga ttggacctga aagaacgtgt tgtctgtg
18601 acaaacgtgc aactgtctt tctactcat cagatactta tgcctgctgg aatcattctg
18661 tgggtttga ctatgtctat aaccattta tgattgatgt tcagcagtgg ggctttacgg
18721 gtaaccttca gagtaacct gaccaacatt gccaggta tggaaatgca catgtggota
18781 gtgtgatgc tatcatgact agatgttag cagtcctga gtgcttgtt aagcgcgtg
18841 attgtctgt tgaataacct attataggag atgaactgag ggttaattct gctgcagaa
18901 aagtacaaca catggtgtg aagtctgcat tgcctgctga taagttcca gttctcatg
18961 acattgaaa tcaaaggct atcaagtgtg tgcctcaggc tgaagtagaa tggaaagtct
19021 acgatgtca gccatgtat gacaaagctt acaaaataga ggaactctt tattctatg
19081 ctacacatca cgataaattc actgatgtg ttgtttgt ttggaattgt aacgtgatc
19141 gttaccagc caatgcaatt gtgtgtagt ttgacacaag agtctgtca aactgaact
19201 taccaggctg tgatgggtg agttgtatg tgaataagca tgcattccac actccagct
19261 tcgataaaag tgcattact aattaaagc aattgcctt ctttactat tctgatagtc
19321 ctgtgtgac tcatggcaaa caagtagtgt cggatattga ttatgtcca ctcaaatctg
19381 ctacgtgtat tacacgatgc aattagggtg gtgctgttg cagacacat gcaaatgagt
19441 accgacagta ctggatgca tataatatga tgattctgc tggattagc ctatggatt
19501 acaacaatt tgatactat aacctgtga atacattac caggttacag agtttagaaa
19561 atgtggctta taatgtgtt aataaaggac actttgatgg acacgccggc gaagcacctg

19621 ttccatcat taataatgct gttacacaa aggtagatgg tattgatgtg gagatcttg
 19681 aaaataagac aacacttcct gtaaatgtg cattgagct ttgggctaag cgtaacatta
 19741 aaccagtgcc agagattaag atactcaata atttgggtgt tgatatcgct gctaatactg
 19801 taatctggga ctacaaaaga gaagccccag cacatgtatc tacaataggt gtctgcacaa
 19861 tgactgacat tgccaagaaa cctactgaga gtgctgttc ttacttact gtctgttg
 19921 atggtagagt ggaaggacag gtagacctt ttgaaacgc ccgtaatggg gtttaataa
 19981 cagaagggtc agtcaaaggc ctaacacctt caaagggacc agcacaagct agcgtcaatg
 20041 gagtcacatt aattggagaa tcagtataaa cacagtttaa ctactttaag aaagtagacg
 20101 gcattattca acagttgcct gaaacctact ttactcagag cagagactta gaggatttta
 20161 agcccagatc acaaatggaa actgacttcc tcgagctcgc tatggatgaa ttcatcacgc
 20221 gatataagct cgagggtctat gccttcgaac acatcgttta tggagatttc agtcatggac
 20281 aacttggcgg tcttcattta atgataggct tagccaagcg ctcaacagat tcaccactta
 20341 aattagagga ttatccct atggacagca cagtgaataa ttactcata acagatgcgc
 20401 aaacagggtc atcaaatgt gtgtgtctg tgattgatct ttacttgat gactttgtc
 20461 agataataaa gtcacaagat ttgtcagtga ttcaaaagt ggtcaagggt acaattgact
 20521 atgctgaaat ttattcatg ctttgggtga aggatggaca tgtgaaacc ttctaccaa
 20581 aactacaagc aagtcgagcg tggcaaccag gtgtgcat gcctaactg tacaagatgc
 20641 aaagaatgct tctgaaaag tgtgacctc agaattatgg tgaataatgct gttatacaa
 20701 aaggaataat gatgaatgtc gcaaatgata ctcaactgtg tcaatactta aatacactta
 20761 ctttagctgt accctacaac atgagagtta ttactttgg tctggctct gataaaggag
 20821 ttgcaccagg tacagctgtg ctacagacaat ggttgccaac tggcacacta ctgtcgatt
 20881 cagatcttaa tgacttcgtc tccgacgcat atttacttt aattggagac tgtgcaacag
 20941 tacatacggc taataaatgg gacctatta ttacgatat gtatgacctt aggaccaaac
 21001 atgtgacaaa agagaatgac tctaaagaag ggttttcac ttatctgtgt ggattataa
 21061 agcaaaaact agccctgggt ggttctatag ctgtaaagat aacagagcat tcttggatg
 21121 ctgacctta caagcttatg ggccattct catgtggac agctttgtt acaaatgtaa
 21181 atgcatcatc atcggaagca tttaattg gggctaacta tcttggcaag ccgaaggaa
 21241 aaattgatgg ctatacatg catgctaact acatttctg gaggaacaca aatcctatcc
 21301 agttgtctc ctattcactc ttgacatga gcaatttcc tctaaatta agaggaactg
 21361 ctgtaatgtc tcttaaggag aatcaaatca atgatgat ttattctct ctggaaaag
 21421 gtaggcttat cattagagaa aacaacagag ttgtggttc aagtatatt ctgttaaca
 21481 actaaacgaa catgtttatt ttctattat ttctactct cactagtgtt agtgacctg
 21541 accggtgcac cactttgat gatgtcaag ctctaatta cactcaacat actcatcta
 21601 tgaggggggt ttactatct gatgaaatt ttatgcaga cacttttat ttaactcagg
 21661 atttattct tccatttat tctaattga cagggttca tactattaat catacgttg
 21721 gcaaccctgt cataccttt aaggatggtt ttattttgc tgccacagag aaatcaaatg
 21781 ttgtccgtgg ttgggtttt ggttctacca tgaacaacaa gtcacagtcg gtgattatta
 21841 ttaacaattc tactaatgtt gttatacag catgtaactt tgaattgtg gacaacctt
 21901 tcttgcgtgt ttctaaacc atgggtacac agacacatac tatgatattc gataatgcat
 21961 ttaattgcac ttcgagtac atatctgat cctttcgtc tgatgttca gaaaagtcag
 22021 gtaatttaa acacttacga gagtttgtt taaaaataa agatgggtt ctctatgtt
 22081 ataagggtc tcaacctata gatgtagttc gtatctacc ttctgggtt aacacttga
 22141 aacctattt taagtgcct ctgtgatta acattacaaa tttagagcc attcttacg
 22201 cctttcacc tgcacagac atttggggca cgtcagctgc agcctattt gttggctatt
 22261 taaagccaac tacatttat ctcaagtat atgaaaatg tacaatcaca gatgctgtg
 22321 attgttca aaatccact gctgaactca aatgctctgt taagagctt gagattgaca
 22381 aaggaattta ccagacctt aatttcaggg ttgtccctc aggagatgtt gtgagattcc
 22441 ctaatattac aaacttgtt cctttggag aggttttaa tgctactaaa ttccctctg
 22501 tctatgcatg ggagagaaaa aaaatttcta attgtgttc tgattactct gtgctctaca
 22561 actcaacatt tttcaacc ttaagtgt atggcgttc tgccactaag ttgaatgatc
 22621 ttgtctctc caatgtctat gcagattct ttgtagtcaa gggagatgat gtaagacaaa
 22681 tagcgcagg acaactggt gttattgtc attataatta taaattgcca gatgattca
 22741 tgggttgtt cctgtctgg aatactagga acattgatgc tacttcaact ggttaattat
 22801 attataaata taggtatct agacatggca agctaggcc cttgagaga gacatatcta
 22861 atgtgcctt cctccctgat ggcaaacctt gcacccacc tgccttaaat tgtattggc
 22921 cattaaatga ttatgggtt tacaccacta ctggcattg ctaccaacct tacagattg

22981 tagtacttcc tttgaactt ttaaatgcac cggccacggg ttgtggacca aaattatcca
 23041 ctgaccttat taagaaccag tgtgtcaatt ttaattttaa tggactcact ggtactgggtg
 23101 tgttaactcc ttcttcaaag agatttcaac catttcaaca atttggccgt gatgtttctg
 23161 atttactga ttccgttcga gatcctaaaa catctgaaat attagacatt tcaccttgcg
 23221 ctttggggg tgaagtgtta attacacctg gaacaaatgc ttcatctgaa gttgctgttc
 23281 tataatcaaga tgttaactgc actgatgtt ctacagcaat tcatgcagat caactcacac
 23341 cagcttggcg catatattct actggaaaca atgtattcca gactcaagca ggctgtctta
 23401 taggagctga gcatgtcgac acttcttatg agtgcgacat tcctattgga gctggcattt
 23461 gtgctagtta ccatacagtt tctttattac gtagtactag ccaaaaatct atttggcct
 23521 atactatgtc tttaggtgct gatagtcaa ttgcttactc taataacacc attgctatac
 23581 ctactaactt tcaattagc attactacag aagtaatgcc tgttctatg gctaaaacct
 23641 ccgtagattg taatatgtac atctgcggag atttactga atgtgctaatt ttgcttctcc
 23701 aatatggtag ctttgcaca caactaaatc gtgcactctc aggtattgct gctgaacagg
 23761 atcgcaacac acgtgaagtg ttgcctcaag tcaaacaaat gtacaaaacc ccaacttga
 23821 aatatttgg tggtttaatt ttctacaaa tattacctga cctctaaag ccaactaaga
 23881 ggtcttttat tgaggacttg ctcttaata aggtgacact cgctgatgct ggcttcatga
 23941 agcaatatgg cgaatgccta ggtgatatta atgctagaga tctcattgt ggcagaagt
 24001 tcaatggact tacagtgtg ccacctctgc tcaatgatga tatgattgct gcctacactg
 24061 ctgctctagt tagtggtact gccactgctg gatggacatt tgggtctggc gctgctctc
 24121 aaataccctt tgctatgcaa atggcatata ggttcaatgg cattggagtt acccaaatg
 24181 ttctctatga gaaccaaaaa caaatcgcca accaatttaa caaggcgatt agtcaaatc
 24241 aagaatcact tacaacaaca tcaactgcat tgggcaagct gcaagacgtt gtaaccaga
 24301 atgctcaagc attaaacaca ctgttaaac aacttagctc taatttggg gcaatttcaa
 24361 gtgtgctaaa tgatacctt tcgcgacttg ataaagtga ggcgaggga caaattgaca
 24421 ggttaattac aggcagactt caaagcctc aaacctatgt aacacaaca ctaatcaggg
 24481 ctgctgaaat cagggtctct gctaacttg ctgctactaa aatgtctgag tgtgtcttg
 24541 gacaatcaaa aagagttgac tttgtggaa agggctacca ccttatgtcc ttcccacaag
 24601 cagccccgca tgggtgtgc ttctacatg tcacgtatgt gccatcccag gagaggaact
 24661 tcaccacagc gccagcaatt tgcataag gcaagcata ctccctcgt gaagggttt
 24721 ttgtgttaa tggcactct tggtttata cacagaggaa ctctttct ccacaaataa
 24781 ttactacaga caatacatt gtctcaggaa attgtatgt cgttatggc atcattaaca
 24841 acacagtta tgatcctctg caacctgagc ttgactcatt caaagaagag ctggacaagt
 24901 acttcaaaaa tcatatcat caagatgtg atcttggcga catttcaggc attaacgct
 24961 ctgtctcaa cattcaaaaa gaaattgacc gcctcaatga ggtcgctaaa aatttaaag
 25021 aatcacicat tgacctcaa gaattgggaa aatatgagca atatattaaa tggccttgg
 25081 atgttggct cggcttcatt gctggactaa ttgccatcgt catggttaca atcttgctt
 25141 gttgcatgac tagttgtgc agttgcctca aggggtcatg ctcttgggt tcttgctga
 25201 agttgatga ggtgactct gagccagtc tcaagggtgt caaattacat tacacataaa
 25261 cgaactiatg gattgttta tgagatttt tactcttga tcaattactg cacagccagt
 25321 aaaaattgac aatgctctc ctgcaagtac tgtcatgct acagcaacga taccgctaca
 25381 agcctcactc ccttcggat ggctgttat tggcgttgca ttcttgctg ttttcagag
 25441 cgctacaaa ataattgag tcaataaaag atggcagcta gcccttata agggcttcca
 25501 gttcattgc aattactgc tgctattgt taccatctat tcacatctt tgcctgtgc
 25561 tgcaggtagt gaggcgcaat ttgttacct ctatgcctg atatatttc tacaatgcat
 25621 caacgcatgt agaattatta tgagatgtg gcttgttg aagtgcaaat ccaagaacc
 25681 attactttat gatgccact acttgttg ctggcacaca cataactatg actactgtat
 25741 accatataac agtgcacag atacaattgt cgttactgaa ggtgacggca tttcaacacc
 25801 aaaactcaaa gaagactacc aaattgggtg ttattctgag gataggcact cagggtgtta
 25861 agactatgtc gttgtacatg gctattcac cgaagttac taccagctg agtctacaca
 25921 aattactaca gacactggta ttgaaaatgc tacattctc atcttaaca agcttgttaa
 25981 agaccacccg aatgtgcaaa tacacacaat cgacggctct taggagttg ctaatccagc
 26041 aatggatcca attatgatg agccgacgac gactactagc gtgccttgt aagcacaaga
 26101 aagtgaglac gaacttatgt actattcgt ttcggaagaa acaggtaagt taatagttaa
 26161 tagcgtactt cttttcttg ctctgtgtt atcttgcta gtcacactag ccactctac
 26221 tgcgcttga ttgtgtcgt actgctgcaa tattgttaac gtgagtttag taaaaccaac
 26281 ggtttacgtc tactgcgtg taaaaatct gaactctct gaaggagtc ctgatctct

26341 ggctaaacg aactaactat tattattatt ctgttggaa cttaacatt gcttatcatg
26401 gcagacaacg gtactattac cgttgaggag cttaacaac tcttgaaca atggaaccta
26461 gtaatagggt tctattcct agcctggatt atgttactac aattgccta ttctaacgg
26521 aacaggttt tgtacataat aaagctgtt ttctctggc tcttggcc agtaacactt
26581 gctgtttt tgttctgc tgtctacaga attaatggg tgactggcg gattgctg
26641 gcaatggctt gtatttagg ctgtatgg cttagctact tcttgcctt cttcaggctg
26701 ttgtctgta cccgctcaat gtggtcatt aaccagaaa caaacattt tctcaatgtg
26761 cctctccggg ggacaattgt gaccagaccg ctcatggaaa gtgaactgt cattggtgct
26821 gtgatcatt gtggtcact gcgaatggc ggacactccc tagggcgctg tgacattaag
26881 gacctgcaa aagagatcac tgtggctaca tcacgaacgc ttcttatta caaatagga
26941 gcgtcgagc gtgtaggcac tgattcagg tttgtgcat acaaccgcta cgtattgga
27001 aactataat taaatacaga ccacgccgt agcaacgaca atattgctt gctagtacag
27061 taagtacaa cagatgtt atctgttga ctccagggt acaatagcag agatattgat
27121 tatcattatg aggacttca ggattgctat ttggaattt gacgtataa taagtcaat
27181 agtgagacaa ttattagc ctctaactaa gaagaattat tggagttag atgatgaaga
27241 acctatggag ttgattat cataaacga acatgaaaat tttctctt ctgacattga
27301 ttgtattac atcttgcag ctatacact atcaggagt ttttagagg acgactgtac
27361 tactaaaaga acctgccc tcaggaacat acgagggcaa tcaaccatt caccctctg
27421 ctgacaata atttgacta acttgacta gcacacact tcttttct tgtctgacg
27481 gtactcgaca tacctatcag ctgctgcaa gatcagttt accaaaact tcatcagac
27541 aagaggagg tcaacaag ctctctgc cacttttct catgttct gctctagtat
27601 ttttaact tttctacc attagagaa agacagaat aatgagctca cttaattga
27661 ctctattt tcttttag ctttctgt attcctgt ttaaatgc ttattatt
27721 ttggtttca ctgaaatcc aggatctaga agaactgt accaaagt aaacgaacat
27781 gaaacttct attgtttga ctgtattt tctatgcagt tcatatgca ctgtagtaca
27841 gcgtgtgca tctaataaac ctatgtgt tgaagatct tgaaggtag aacactaggg
27901 gtaatact tagcactgt tggcttgt ctctaggaaa ggtttacct ttcatagat
27961 ggcacactat ggtcaaaca tgcacaccta atgtactat caactgtcaa gatccagctg
28021 gtggtgctt tatagctagg tttgttacc tcatgaagg tcacaaact gctgcattta
28081 gagacgtact tttgtttta aataaacgaa caaatlaaaa tgtctgataa tggacccaa
28141 tcaaaccaac gtatgcccc ccgattaca ttggtggac ccacagatt aactgacaat
28201 aaccagaatg gaggacgcaa tggggcaagg ccaaacagc gccgaccca aggtttacc
28261 aataactct cgtcttgg ttacagctct actcagcat gcaaggagga acttagatt
28321 cctcagggcc agggcgttc aatcaacacc aatagtgt cagatgacca aattggctac
28381 taccgaagag ctacccgac agttcgtgt ggtgacggca aatgaaaga gctcagcccc
28441 agatgtact tctattacct aggaactgg ccagaagctt cacttcccta cggcgctaac
28501 aaagaaggca tctatgggt tgcaactgag ggagcctga atacaccaa agaccacatt
28561 ggcacccgca atctaata caatgtgcc accgtgctac aacttctca aggaacaaca
28621 ttccaaaag gcttctacgc agagggaagc agaggcggca gtcaagctt tctcgtctc
28681 tcatcacgta gtgcggtta tcaagaaat tcaactctg gcagcagtag gggaaattt
28741 cctgctcga tggctagcgg aggtgtgaa actgcccctg cgtattgt gctagacaga
28801 ttgaaccagc ttgagagcaa agttctgt aaaggccaac aacaacaagg ccaactgtc
28861 actaagaaat ctgctgtga ggcattaaa agcctcgc aaaaacgtac tgccacaaa
28921 cagtacaacg tactcaagc atttgggaga cgtgttccag acaaaccca aggaaattt
28981 ggggaccaag acctaatcag acaaggaact gattacaaac attgccgca aattgcacaa
29041 ttgtctcaa gtgcctctg attcttga atgtacgca ttggcatgga agtcacacct
29101 tgggaacat ggctgacta tcatggagcc attaatgt atgacaaaga tccacaatt
29161 aaagacaacg tcatctgt gaacaagcac attgacgat acaaacatt cccaccaaca
29221 gagcctaaa aggacaaaa gaaaagact gatgaagct agccttgc gcagagacaa
29281 aagaagcagc cactgtgac tcttctct cggctgaca tggatgatt ctccagacaa
29341 ctcaaaatt catgagtgg agctctgt gattcaact aggcataaac actcatgat
29401 accacacaag gcagatggg tatgtaacg tttcgcaat tccgttacg atacatagt
29461 tactctgt cagaatgat tctgtact aaacagcaca agtaggtta gtaactta
29521 atctacata gcaatctta atcaatgt aacattagg aggactgaa agagccacca
29581 catttcatc gaggccagc ggagtacgat cgagggtaca gtgaataat ctagggagag
29641 ctgccttat ggaagagccc taatgtgaa aattaattt agtagtcta tcccatgtg

29701 attttaatag cttcttagga gaatgacaaa aaaaaaaaaa aaaaaaaaaa a
//





Fig. 5. The Subgenomic HCV Replicon Used to Test The Efficacy of siRNA in Human Liver Cells



Neo: neomycin phosphotransferase gene

Luc: fruit fly luciferase

EMCV: internal ribosome entry site taken from EMCV

NS3, NS4A, NS4B, NS5A, and NS5B: HCV nonstructural proteins

**Fig. 6. The Effect of siRNA₅ on HCV Replication
In Huh 5-2 Cells**




Fig. 7. Sequence Specificity Required for Mediating RNA Interference in Huh7 Cells




Fig. 8. The Effect of siRNA5 of Cell Viability Measured by Cellular ATPase Activity




Fig. 9. The Effect of siRNA₅ on HCV Replication in Huh-7 Cells Measured by HCV RNA Assay




Fig. 10




Fig. 11




Fig. 12




Fig. 13





Fig. 14






Fig. 15





Fig. 16

The Effect of siRNA₅ on HCV Replication In Huh 5-2 Cells

5-2 cells at 70 % confluent

Luc activity Norm.
to a transfection control



mock transfected

t-siRNA 5-0.1

t-siRNA 5-1

t-siRNA 5-10

t-siRNA 5-100

s-siRNA SIN-100